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Abstract
A strain-release-driven, cation-templated intramolecular nucleophilic addition of tethered 
alkoxides to prochiral cyclopropenes is described. Employment of chiral β- and γ-amino 
alkoxides allowed for highly diastereoselective assembly of a small series of enantiopure 
cyclopropane-fused oxazepanones. It was shown that the chiral center at C-4 plays a crucial role in 
controlling desymmetrization of the cyclopropenyl moiety, instigated by a profound potassium-
templated effect. The preliminary biological activities of the new cyclopropane-fused medium 
heterocycles against Gram-positive bacteria, Gram-negative bacteria, mycobacteria, cancer cells, 
and fungus were evaluated.
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Advances in base-assisted additions of heteroatom-based nucleophiles to cyclopropenes 
made available novel stereo-defined cyclopropyl scaffolds,1 possessing oxygen,2 nitrogen,3 
sulfur,4 or halogen5 entities, that complement transition-metal-catalyzed cyclopropanation 
methodologies.6,7 Both intermolecular (Scheme 1, eq 1) and intramolecular (Scheme 1, eq 
2) addition of tethered nucleophiles, employing carbon-8 or oxygen-based species, has been 
reported.9,10 In all these studies achiral tethered nucleophilic entities were used for 
cyclizations affording racemic products. A diastereoselective 8-endo-trig cycloaddition 
using chiral cyclopropene precursor 8 has been demonstrated (Scheme 1, eq 3),10 while a 
complementary approach involving intramolecular nucleophilic addition of tethered chiral 
alkoxides to prochiral cyclopropene moieties has not been fully explored. To date, only two 
examples were communicated by our group,11 using cyclopropene 11 generated in situ via 
1,2-elimination of bromocyclopropane 10 (Scheme 2). The limited availability of chiral 
precursors 10 warranted further studies to adapt this methodology to more stable, isolable 
cyclopropenes accessible via the metal-catalyzed cyclopropenation reactions.12 Herein, we 
report the development of a synthetic approach that allows for modular assembly of chiral 
medium-sized heterocycles 6 and 12 bearing a fused cyclopropane moiety. It should be 
pointed out that fused oxazepines are a very important class of biologically active molecules 
that display diverse pharmacological activities.1 Known bioactivities for this class of 
compounds include anticonvulsant, antimicrobial, anticancer, and antipsychotic agents and 
calcium antagonists and neuroprotectors. Development of new approaches to these important 
molecules, especially stereoselective, can lead to the discovery of new privilege medicinal 
structures. Preliminary biological studies of our new scaffolds revealed several hits showing 
promising antimicrobial activity against Mycobacterium abscessus,13 a rapid-growing highly 
virulent chemotherapy-resistant mycobacterial pathogen.
RESULTS AND DISCUSSION
We have recently communicated an efficient synthesis of medium cyclic ethers 6 via a 
formal nucleophilic cyclization of bromocyclopropanes 4 (Scheme 1, eq 2),9a involving an 
in situ base-assisted generation of reactive cyclopropene 5, which, once formed, is 
immediately trapped by a tethered alkoxide. Our computational studies suggested that the 
mechanism of this strain-release-driven reaction involves a transition state where the 
potassium ion is coordinated to both alkoxide and amide oxygens, as well as to the carbon 
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atom bearing a partial negative charge (C-8) (TS1 in Scheme 6). It was expected and 
confirmed experimentally that the templating effect induced constraints on the rotors in the 
tether, making the cyclization pathway more favorable vis-a-vis oligo- and polymerization. 
Furthermore, the rigidity of such activated complexes allowed for high diastereoselectivity 
of the newly formed stereogenic centers when chiral amino alcohol-tethered prochiral 
cyclopropenes are used as substrates. In our preliminary communication,11 we have 
demonstrated two examples of such cyclization of bromocyclopropanes 10 decorated with 
(R)-phenylglycinol (R3 = Ph, R4 = H) and (R,R)-pseudoephedrine (R3 = Me, R4 = Ph) side 
chains. Highly stereoselective formation of bicyclic products 12 was observed in both cases, 
while diastereomers 13 were never detected.
Further exploration of this approach has met with synthetic challenges and was essentially 
unrewarded. Numerous experimentations proved that only 1-methyl-2-bromocyclopropane 
carboxylic acid is fairly suitable for the preparation of starting amides 10 (R1 = Me).14 In 
situ generation of cyclopropenyl amides 11 via 1,2-dehydrohalogenation using analogues of 
10 with R1 ≠ Me has severe limitations rendering this synthetic pathway impractical. 
Accordingly, we embarked on an alternative route to cyclopropenyl amides 11, via the 
Rh(II)-catalyzed [2 + 1]-cycloaddition of diazoacetates with trimethylsilylacetylene,15 which 
was improved and tailored to our systems.16 This approach was benchmarked on racemic 
cyclopropene amides derived from achiral amino alcohols. To this end, available 1-
arylcycloprop-2-ene-1-carboxylic acids15,16 14 were derivatized with N-protected 2-
aminoethanols and 3-aminopropanols 15 to afford the corresponding amides 16, which were 
used crude in the subsequent base-assisted cyclization (Scheme 3). We first probed the 
cyclization of amide 16aa, which reacted uneventfully affording 
oxazabicyclo[5.1.0]octanone 17aa as a sole product in good yield (Figure 1). Note that 18-
crown-6 ether was not used in this case, as compared to the earlier examples depicted in 
Scheme 1 and 2,9–11 as this catalyst is required only in the 1,2-dehydrobromination step for 
efficient generation of cyclopropene. With the positive initial results in hand, we moved on 
to evaluate the effect of substituents at nitrogen (R2) and sp3-hybridized carbon of 
cyclopropene (R1) on the cyclization propensity of cyclopropenylamides. We were pleased 
to see that N-methyl (17ab, 17bb, 17cb) and various N-benzyl 2-oxa-5-
azabicyclo[5.1.0]octan-6-ones (17ac, 17ad, 17af, 17ba, 17ca) were efficiently obtained via 
this approach (Figure 1). N-Phenyl derivative 17af was produced only in poor yield, which 
was attributed to a facile base-assisted hydrolysis of the C−N bond in anilides, as noted 
previously.14 This side reaction is suppressed in electron-rich anilides, so cyclization of p-
anisidine derivatives proceeded smoother, affording better yields of oxazepanones 17ag and 
17bg (Figure 1). Tethered 3-aminopropanols underwent 8-exo-trig cyclization efficiently 
under the same reaction conditions to give oxazocanones 17ah, 17bh, 17bi, and 17ch 
(Figure 1).
Having mapped the substrate scope, we next investigated the possibility of a 
diastereoselective nucleophilic 7-exo-trig cyclization of tethered chiral alkoxides with 
prochiral cyclopropenes.17 The two-carbon-atom tether allows for independent installation 
of two stereogenic centers, which gives rise to four different modes depicted in Scheme 4. 
Thus, derivatives of chiral amino ethanols with (S)-configuration at C-2 (18) can potentially 
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produce two products: (1S,4S,7S)-19 or (1R,4S,7R)-20 (mode I). Likewise, (R)-
configuration at C-1 in the amino alcohol tether of 21 would give rise to diastereomers (1S,
3R,7S)-22 or (1R,3R,7R)-23, respectively (mode II). Two additional modes are possible 
when the diastereoselectivity is induced in the presence of two contiguous chiral centers at 
C-1 and C-2 of the amino alcohol tether. Thus, threo-(24) could potentially afford products 
(1S,3S,4S,7S)-25 or (1R,3S,4S,7R)-26 (mode III), while erythro-(27) could provide (1S,3R,
4S,7S)-28 and (1R,3R,4S,7R)-29, respectively (mode IV) (Scheme 4). The following 
discussion addresses all the above-mentioned cyclization modes in detail.
To probe mode I, a set of condensation reactions between 1-arylcycloprop-2-ene-1-
carboxylic acids (14a−c) and chiral amino alcohols 30b−d were carried out, and thus 
obtained chiral cyclopropenes 18 were used crude in the cyclization (Scheme 5) under the 
standard reaction conditions described above (Scheme 3). We were very pleased to find that, 
in all cases, the enantiomerically pure (3S,6S,7S)-2-oxa-5-azabicyclo-[5.1.0]-octan-6-ones 
19 were obtained as sole products (3R,6R,7R enantiomer was obtained for 19bc, originated 
from (R)-phenylglycinol). None of these reactions produced any detectable amounts of the 
diastereomers 20 (Figure 2). The relative and absolute configuration of compound 19bd was 
unambiguously confirmed by single-crystal X-ray crystallography.18
Our rationale for the origins of the high diastereoselectivity obtained in cyclization mode I is 
shown in Scheme 6. Our earlier computational studies performed on achiral models 
suggested that the transition state in 7-exo-trig cyclization (TS1) has a very rigid pseudoboat 
conformation, stabilized by a three-center coordinated potassium cation bound through the 
alkoxide and carbonyl oxygens as well as the anionic carbon atom.9a Assuming the same 
transition state model is realized for the chiral substrates in the present studies, a 
nucleophilic attack at the now diastereotopic C-7 or C-8 would result in two nonequivalent 
reaction pathways a and b, respectively (Scheme 6). Path a, affording product 19, operates 
via a lower-energy transition state TS2a, in which substituent R3 at C-4 assumes the 
thermodynamically more favored, pseudoequatorial (bowsprit) conformation. The 
alternative, higher-energy transition state TS2b, resulting from nucleophilic attack b, forces 
the R3 group into a pseudoaxial (flagpole) position where it experiences a strong syn-
pentane interaction with hydrogen at C-8, which disfavors formation of product 20.
To test mode II, (R)-2-(benzylamino)-1-phenylethan-1-ol (31) was condensed with 
cyclopropenylcarboxylic acid 14b, and the resulting amide 21b was subjected to the base-
assisted cyclization. A 1:4 ratio of two isomeric products, 22b and 23b, was obtained 
(Scheme 7). Configurations of both products were unambiguously assigned by 2D NOESY 
experiments.18 A mechanistic scenario consistent with the observed marginal 
diastereoselectivity is outlined in Scheme 8. It is believed that the unfavorable 1,3-diaxial 
interaction between substituent R4 at C-5 and the R2 group at nitrogen in the seven-
membered complex TS3a (resulting from path a) is not as prohibitive as in cyclohexyl 
analogues. As a result, 22 is produced as a minor product. An alternative, major pathway b 
proceeding via transition state TS3b, in which substituent R4 at the stereogenic center is free 
of the unfavorable interactions, gives rise to major product 23 (Scheme 8).
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Next, we tested modes III and IV on cyclopropenyl carboxamide derivatives prepared from 
cyclopropene carboxylic acids 14a−d and (+)- or (−)-pseudoephedrine (32 or ent-32) and 
(−)-ephedrine (33). Cyclization of these substrates provided oxazepanones 25 (or ent-25) 
and 28, respectively, as sole products in excellent yields (Scheme 9, Figure 3). Single-crystal 
X-ray diffraction analysis unambiguously con-firmed the absolute configurations of products 
25c and 28c.18 The origins of high diastereoselectivity in the 7-exo-trig nucleophilic 
cyclization producing 25 (mode III) are analyzed in Scheme 10. It is believed that the 
nucleophilic attack at C-7 (path a) is highly preferred due to a more favored transition state 
TS4a, in which both substituents R3 and R4 occupy a pseudoequatorial position. A 
complementary path b would lead to a much more energetic transition state TS4b, in which 
substituent R3 in a flagpole orientation is experiencing steric repulsions with hydrogen at 
C-8 (Scheme 10), similar to that described above for mode I (Scheme 6). The 1,3-diaxial 
interaction between substituents R2 and R4 could be another contributing factor to 
destabilization of TS4b. This effect, however, is not expected to be significant for small N-
substituents, such as a methyl group.
Finally, the high selectivity observed in cyclization mode IV is rationalized as follows 
(Scheme 11). Transition state TS5a resulting from the nucleophilic attack at C-7 (path a) is 
rather favorable, since the 1,3-diaxial interaction between substituents R2 and R4, as was 
stated above, is quite insignificant for nonbulky R2 groups. The alternative transition state 
TS5b, resulting from an attack at C-8 (path b), experiences prohibitive steric interactions 
with a flagpole substituent R3 (Scheme 11). Arguably, in all four cyclization modes analyzed 
above, the stereoselectivity is greatly influenced by configuration of the stereogenic center at 
C-4 and the R3 group, while the C-5 substituent R4 plays a modest role, at least for 
derivatives with a nonencumbered substituent on the nitrogen. The strong cation-templating 
effect elicits conformational rigidity of the transition state and amplifies the asymmetric 
induction arising from a rather remote chiral center, which ultimately allows for the efficient 
desymmetrization of the cyclopropenyl moiety.
The obtained enantiopure 2-oxa-5-azabicyclo[5.1.0]octan-6-ones constitute very attractive 
biological probes as this unique heterocyclic scaffold just recently emerged on the chemical 
space map. Accordingly, we performed a preliminary biological evaluation of a few 
representative compounds for antimicrobial and anticancer activities. The antiproliferative 
activity was assessed by using the cancer cell line, HeLa, as a model for human cervical 
adenocarcinoma, through the measurements of mitochondrial dehydrogenase activities using 
the MTT method.19 In addition, the synthesized compounds were tested against 
Staphylococus epidermidis (ATCC 75984) and Escherichia coli (ATCC 25922), where 
minimum inhibitory concentrations (MICs) were determined by the broth micro-dilution 
method using MTT assay.20 Since the described compounds bear some similarity with 
azepines known to possess activity against mycobacteria,21 we also tested products 19, 25, 
and 28 against Mycobacterium abscessus (ATCC 19977) by MTT assay. The potency of 
synthesized compounds against yeasts was also evaluated using Candida albicans (ATCC 
26555).
Our preliminary tests revealed that none of these compounds demonstrated any activity 
against Candida albicans, Staphylococus epidermidis, or Escherichia coli up to 100 μM nor 
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significant cytotoxicity on HeLa cells. However, promising activity against Mycobacterium 
abscessus was observed for selected 2-oxa-5-azabicyclo[5.1.0]octan-6-ones (Table 1). The 
latter finding, coupled with apparent low general toxicity against cultured human cells, set 
the grounds for further SAR studies.
CONCLUSION
A potassium-templated, intramolecular nucleophilic addition of alkoxides to isolable, 
prochiral cyclopropenes has been developed. The scope of this cyclization and the 
mechanism of enantiomeric induction were investigated on a series of tethered chiral 
alkoxides. Three out of four tested chiral cyclization modes provided a highly efficient 
asymmetric induction, governed by the chiral center at C-4 and controlled by the strong 
chelating effect of potassium. The obtained optically active 2-oxa-5-
azabicyclo[5.1.0]octan-6-ones were tested against representative mycobacterial infection-
causing organisms as well as other bacteria, pathogenic fungi, and human cultured cell lines. 
The biological profile exhibited by some of these unique chiral cyclopropane-fused medium-
sized heterocycles is noteworthy and is currently being further explored in our laboratories.
EXPERIMENTAL SECTION
General.
NMR spectra were recorded on a Bruker Avance DRX-500 (500 MHz) with a dual carbon/
proton cryoprobe (CPDUL), Bruker III (400 MHz) equipped with BBO probe. 13C NMR 
spectra were registered with broadband decoupling. The (+) and (−) designations represent 
positive and negative intensities of signals in 13C DEPT-135 experiments. IR spectra were 
recorded on a ThermoFisher Nicolet iS 5 FT-IR spectrometer. HRMS was carried out on an 
LCT Premier (Micromass Technologies) instrument employing ESI TOF detection 
techniques. Glassware used in moisture-free syntheses was flame-dried in a vacuum prior to 
use. Column chromatography was carried out on silica gel (Sorbent Technologies, 40−63 
mm). Precoated silica gel plates (Sorbent Technologies Silica XG 200 mm) were used for 
TLC analyses. Anhydrous dichloromethane was obtained by passing degassed commercially 
available HPLC-grade inhibitor-free solvent consecutively through two columns filled with 
activated alumina and stored over molecular sieves under nitrogen. Water was purified by 
dual-stage deionization followed by dual-stage reverse osmosis. Anhydrous THF was 
obtained by refluxing commercially available solvent over calcium hydride followed by 
distillation in a stream of dry nitrogen. 1-Phenylcycloprop-2-ene-1-carboxylic acid (14a),22 
1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (14b),6d and (S)-2-(benzylamino)-4-
methylpentan-1-ol (30d)23 were synthesized according to the previously published 
procedures and had physical and spectral properties identical to those earlier reported. 
Syntheses of 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c), 1-
(naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (14d), and 2-((5-bromo-2-
fluorobenzyl)amino)ethan-1-ol (15e) are described herein.18 All other reagents and solvents 
were purchased from commercial vendors and used as received. See Supporting Information 
for the spectral charts and X-ray crystallography data.
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Biological Studies: Materials and Methods.
All culture cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA).
Cell Culture.—HeLa cells were cultured in DMEM supplemented with 10% fetal bovine 
serum (FBS). To evaluate antiproliferative properties of the synthesized compounds, the 
cells were trypsinized and seeded at 4 × 103 cells per well into 96-well microtiter plates. The 
cells were grown for 24 h before treatment.
Fungal Culture.—Candida albicans (ATCC 26555) was grown overnight in Difco YM 
Broth at 37 °C in a shaking incubator.
Bacterial Cultures.—Mycobacterium abscessus (ATCC 19977) was inoculated in 
Middlebrook 7H9 medium supplemented with 1% ADC enrichment and incubted at 37 °C 
in T25 tissue culture flasks for 72 h. Staphylococus epidermidis and Escherichia coli were 
incubated in Tryptic Soy Broth (TSB) for 6 h at 37 °C.
MTT Assay for HeLa (ATCC CCL-2).—All compounds were dissolved in DMSO at a 
concentration of either 100 or 50 mM prior to cell treatment. The cells were treated at 
concentrations ranging from 0.004 to 100 μM and incubated for 48 h in 200 μL of media. An 
amount of 20 μL of MTT reagent in serum-free medium (5 mg/mL) was added to each well 
and incubated further for 2 h. Media was removed, and the resulting formazan crystals were 
solubilized in 100 μL of DMSO. A490 was measured using a Thermomax Molecular Device 
plate reader. The experiments were performed in quadruplicate and repeated at least twice 
for each compound per cell line. Cells treated with 0.1% DMSO were used as a vehicle 
control, and phenyl arsine oxide (PAO) was used as a positive killing control.
MTT Assay for Candida albicans (ATCC 26555).—Cells were diluted 1:20 in YM 
Broth. 2-Fold serial dilutions were prepared as follows: 1000 μL of cells was added to the 
first well of each 24-well plate, and 500 μL of cells was added to the proceeding wells. 
Compounds were added at a final concentration of 100 μM. 2-Fold dilutions were continued 
across all remaining wells. Cells were incubated for 24 h at 37 °C and then treated with 100 
μL of MTT (5 mg/mL) and incubated for 3 h. An equal volume of premixed solution of 50% 
dimethylformamide with 20% sodium dodecyl sulfate (solubilization solution) was added to 
dissolve the formazan crystals and incubated further for 15 min. The experiments were 
performed in triplicate. Amphotericin B was used as positive kill control, and untreated cells 
served as negative controls.
MTT Assay for Staphylococus epidermidis (ATCC 35984) and Escherichia coli 
(ATCC 25922).—An overnight cell growth was diluted to an optical density of 0.100 at 
A595; cells were further diluted 1:100 in TSB. An amount of 1000 μL of the dilution was 
added to each well of a 12-well plate (except the first well, which received only TSB). Each 
well received one compound at a final concentration of 100 μM. Plates were incubated for 
24 h at 37 °C. Cells were subsequently treated with 100 μL of MTT (5 mg/mL) and 
incubated at 37 °C for 15 min. Solubilization solution was added to dissolve the formazan 
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crystals and incubated further for 15 min. An amount of 50 μg/mL of colistin (PME) was 
used as a positive kill control for E. coli; 50 μg/mL of vancomycin was used as a positive kill 
control for S. epidermidis; and untreated cells served as negative controls. The experiments 
were performed in triplicate.
MTT Assay for Mycobacterium abscessus (ATCC 19977).—Approximately 5.5 × 
105 mycobacteria per mL or a dilution of 1:500 from an overnight growth were plated at a 
final volume of 400 μL/well in 48-well plates. Compounds were initially screened at a 
concentration of 100 μM on M. abscessus. Compounds with antimycobacterial activity at 
100 μM were screened for further activity by adding the selected compounds to cells at a 
concentration of 50 μM and 2-fold serially diluting. The plates were incubated in a shaking 
incubator for 48 h at 37 °C. Following the incubation, 40 μL or 10% w/v of MTT reagent (5 
mg/mL) was added to each of the wells. The plates were incubated for 2 h at 37 °C. An 
amount of 650 μL of solubilization solution was added to each of the wells, and the plate 
was incubated at 37 °C for an additional 12 h. An amount of 100 μL from each well was 
transferred into a clear 96-well microtiter plate, and A595 was read in a Thermomax 
Molecular Device plate reader. Wells containing Middlebrook 7H9 medium and nontreated 
cells served as negative controls, and a well containing 10 μM PAO-treated cells served as a 
positive kill control. The experiments were performed in triplicate.
Synthesis of Starting Materials.
1-(2,4-Dichlorophenyl)-cycloprop-2-ene-1-carboxylic Acid (14c).—Solution 
methyl 1-(2,4-dichlorophenyl)-2-(trimethylsilyl)cycloprop-2-ene-1-carboxylate9b (3.71 g, 
11.77 mmol, 1.00 equiv) in a mixture of methanol and THF (1:1, 100 mL) was stirred at 
0 °C. A 1.5 M aqueous solution of NaOH (102 mL, 153.0 mmol, 13.0 equiv) was added 
dropwise, and the mixture was stirred for 18 h. Organic solvents were then removed under 
vacuum, and the remaining aqueous solution was washed with dichloromethane (3 × 50 
mL). The remaining aqueous phase was acidified with 1 N aqueous HCl to pH 2 and 
extracted with dichloromethane (3 × 50 mL). The combined organic phases were washed 
with brine, dried with MgSO4, filtered, and concentrated. The product was isolated as a 
colorless solid (Rf 0.27, mp 194−195 °C) by column chromatography eluting with a hexane/
EtOAc mixture (2:1). Yield 2.10 g (9.16 mmol, 78%). 1H NMR (400 MHz, CDCl3): δ 11.88 
(s, 1H), 7.36 (d, J = 2.0 Hz, 1H), 7.28 (s, 2H), 7.19 (dd, J = 8.2, 2.1 Hz, 1H), 7.13 (d, J = 8.2 
Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 180.9, 137.9, 135.9, 133.9, 131.2 (+), 129.4 
(+), 127.5 (+), 108.0 (+, 2C), 29.4. FTIR (NaCl, cm−1): 3155 (br), 1697. HRMS (TOF ES): 
found 226.9671, calculated for C10H5Cl2O2 (M − H)− 226.9667 (1.8ppm).
1-(Naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (14d).—This compound was 
synthesized starting from 1-(naphthalen-1-yl)-2-(trimethylsilyl)cycloprop-2-ene-1-
carboxylate9b (3.82 g, 12.9 mmol, 1.00 equiv) according to the procedure described above 
for preparation of acid 14c. The titled product was isolated by column chromatography 
eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf 0.27, mp 144−145 °C). 
Yield 2.23 g (10.6 mmol, 82%). 1H NMR (500 MHz, CDCl3): δ 11.42 (br. s, 1H), 8.08 (d, J 
=8.3 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.55− 7.46 (m, 2H), 7.45 (s, 
2H), 7.41 (t, J = 7.7 Hz, 1H), 7.34 (d, J = 6.9 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 
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181.9, 138.1, 133.9, 132.0, 128.9 (+), 128.2 (+), 126.3 (+), 126.0 (+), 125.9 (+), 125.8 (+), 
124.3 (+), 108.8 (+, 2C), 29.1. FTIR (NaCl, cm−1): 3162 (br), 1691. HRMS (TOF ES): 
found 209.0593, calculated for C14H9O2 (M− H)− 209.0603 (4.8 ppm).
2-((5-Bromo-2-fluorobenzyl)amino)ethan-1-ol (15e).—5-Bromo-2-
fluorobenzaldehyde (2 mL, 3.42 g, 16.8 mmol, 1.0 equiv), 2-aminoethan-1-ol (1.12 mL, 1.13 
g, 18.5 mmol, 1.1 equiv), and 30 mL of anhydrous methanol were combined and stirred at 
RT overnight. The reaction mixture was cooled to 0 °C; NaBH4 (955 mg, 25.3 mmol, 1.5 
equiv) was added in portions; and the reaction mixture was stirred for 2 h at RT. The 
reaction mixture was concentrated in vacuum and partitioned between 10 mL of water and 
10 mL of dichloromethane. The aqueous phase was then extracted with dichloromethane (2 
× 10 mL). The combined organic phases were washed with brine (10 mL), dried with 
MgSO4, filtered, and concentrated to yield the title compound as a colorless solid (mp 
75−76 °C). Yield 3.34 g (13.5 mmol, 80%). 1H NMR (400 MHz, CDCl3): δ 7.48 (dd, J = 
6.6, 2.5 Hz, 1H), 7.38−7.31 (m, 1H), 6.98−6.88 (m, 1H), 3.83 (s, 3H), 3.70−3.64 (m, 2H), 
2.83−2.76 (m, 2H), 1.95 (br. s, 2H). 13C{1H} NMR (126 MHz, CDCl3): δ 160.3 (d, J = 
246.1 Hz), 133.1 (d, J = 5.0 Hz, +), 131.7 (d, J = 8.2 Hz, +), 129.5 (d, J = 16.4 Hz), 117.3 (d, 
J = 23.6 Hz, +), 116.8 (d, J = 3.6 Hz), 61.1 (−), 50.4 (−), 46.6 (d, J = 2.7 Hz, −). FTIR 
(NaCl, cm−1): 3320 (br), 1236, 1171. HRMS (TOF ES): found 248.0092, calculated for 
C9H12BrFNO (M + H) 248.0086 (2.4 ppm).
Cyclization of Achiral Substrates.
5-Benzyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17aa).—Typical 
Procedure. A flame-dried round-bottom flask was charged with 1-phenylcycloprop-2-ene-1-
carboxylic acid (14a) (500 mg, 3.12 mmol, 1.0 equiv), DMF (2 drops), and freshly distilled 
anhydrous dichloromethane (7 mL) under nitrogen atmosphere. Oxalyl chloride (400 μL, 
592 mg, 4.68 mmol, 1.5 equiv) was then added dropwise, and the mixture was stirred at 
room temperature for 2 h. The solution was concentrated in a stream of nitrogen; the residue 
was subjected to a high vacuum, dissolved in anhydrous dichloromethane (2.0 mL), and 
added dropwise to a stirred solution of 2-(benzylamino)ethan-1-ol (15a) (708 mg, 4.68 
mmol, 1.5 equiv) and triethylamine (1.3 mL, 948 mg, 9.36 mmol, 3.0 equiv) in anhydrous 
dichloromethane (3.0 mL). The reaction mixture was stirred at room temperature for 18 h 
and then partitioned between water (15 mL) and dichloromethane (20 mL). The aqueous 
phase was acidified with 5 mL of 2 N HCl. The organic phase was then washed with 2 N 
HCl (3 × 10 mL). The combined aqueous layers were back-extracted once with 10 mL of 
dichloromethane, which was combined with other organic phases, washed with brine, dried 
with MgSO4, filtered, and concentrated. The product, N-benzyl-N-(2-hydroxyethyl)-1-
phenylcycloprop-2-ene-1-carboxamide (16aa), was filtered through a silica plug using 
EtOAc and was used at the cyclization step as is without additional purification. An oven-
dried 1 mL Wheaton vial was charged with powdered KOH (7.6 mg, 0.136 mmol, 2.0 equiv) 
and anhydrous THF (400 μL). Crude amide 16aa (20 mg, 0.068 mmol) was added as a 
solution in anhydrous THF (400 μL). The mixture was vigorously stirred at 30 °C for 18 h, 
and then the reaction mixture was filtered through short plug of Silica gel eluting with 
EtOAc. The eluate was concentrated in vacuum. The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless oil (Rf = 0.25). 
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Yield 17.6 mg (0.060 mmol, 88%). 1H NMR (500 MHz, CDCl3): δ 7.36−7.26 (m, 7H), 
7.25−7.21 (m, 1H), 7.10−7.08 (m, 2H), 4.71 (q, J = 14.7 Hz, 2H), 3.92 (ddd, J = 15.5, 12.6, 
5.1 Hz, 1H), 3.53 (dd, J = 11.2, 5.1 Hz, 1H), 3.43 (dd, J = 6.3, 3.7 Hz, 1H), 3.41−3.36 (m, 
1H), 3.03 (dt, J = 23.2, 11.6 Hz, 1H), 1.75 (dt, J = 24.0, 12.0 Hz, 1H), 1.49 (dd, J = 6.9, 6.4 
Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.7, 138.0, 137.3, 128.9 (+, 2C), 128.8 (+, 
2C), 128.4 (+, 2C), 127.8 (+), 126.8 (+), 124.7 (+, 2C), 64.4 (−), 59.0 (+), 49.8 (−), 44.9 (−), 
34.9, 22.5 (−). FTIR (NaCl, cm−1): 1651, 1408, 1209, 1057. HRMS (TOF ES): found 
294.1501, calculated for C19H20NO2 (M + H) 294.1494 (2.4 ppm).
5-Methyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ab).—This compound 
was synthesized according to the typical procedure from 1-phenylcycloprop-2-ene-1-
carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 2-(methylamino)ethan-1-ol (15b) 
(141 mg, 1.88 mmol, 1.5 equiv). After extraction and filtration through a silica plug, crude 
N-(2-hydroxyethyl)-N-methyl-1-phenylcycloprop-2-ene-1-carboxamide (16ab) was used at 
the cyclization step as is without additional purification. To this end, amide 16ab (20 mg, 
0.092 mmol) was treated with powdered KOH (10.3 mg, 0.184 mmol). The product was 
isolated by column chromatography eluting with a hexane/EtOAc mixture (1:1) as a 
colorless glass (Rf = 0.21). Yield 17.6 mg (0.081 mmol, 88%). 1H NMR (500 MHz, CDCl3): 
δ 7.34−7.27 (m, 2H), 7.25−7.19 (m, 1H), 7.05 (d, J = 7.9 Hz, 2H), 4.06 (ddd, J = 15.4, 12.7, 
5.0 Hz, 1H), 3.82 (td, J = 11.9, 4.6 Hz, 1H), 3.64 (dd, J = 11.2, 5.0 Hz, 1H), 3.40 (dd, J = 
6.2, 3.6 Hz, 1H), 3.08 (s, 3H), 3.03 (dd, J = 15.4, 4.7 Hz, 1H), 1.66 (dd, J = 6.9, 3.5 Hz, 1H), 
1.45 (t, J = 6.6 Hz, 1H).13C{1H} NMR (126 MHz, CDCl3): δ 170.6, 137.9, 128.9 (+, 2C), 
126.8 (+), 124.7 (+, 2C), 63.3 (−), 58.8 (+), 47.6 (−), 34.9, 34.3 (+), 22.3 (−). FTIR (NaCl, 
cm−1): 1651, 1495, 1260, 1169. HRMS (TOF ES): found 240.1003, calculated for 
C13H15NO2Na (M + Na) 240.1000 (1.2 ppm).
5-(4-Methoxybenzyl)-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ac).—
This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 2-((4-
methoxybenzyl)amino)ethan-1-ol (15c) (339 mg, 1.88 mmol, 1.5 equiv). After extraction 
and filtration through a silica plug crude N-(2-hydroxyethyl)-N-(4-methoxybenzyl)-1-
phenylcycloprop-2-ene-1-carboxamide (16ac) was used at the cyclization step as is without 
additional purification. To this end, amide 16ac (20 mg, 0.062 mmol) was treated with 
powdered KOH (6.9 mg, 0.124 mmol). The product was isolated by column chromatography 
eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf = 0.21, mp 102−104 °C). 
Yield 18.2 mg (0.056 mmol, 91%). 1H NMR (500 MHz, CDCl3): δ 7.33−7.28 (m, 2H), 
7.26−7.20 (m, 3H), 7.09−7.06 (m, 2H), 6.88−6.84 (m, 2H), 4.73 (d, J = 14.5 Hz, 1H), 4.57 
(t, J = 11.7 Hz, 1H), 3.92−3.84 (m, 1H), 3.80 (s, J = 2.5 Hz, 3H), 3.51 (dd, J = 11.1, 5.1 Hz, 
1H), 3.40 (dt, J = 11.1, 5.6 Hz, 1H), 3.34 (ddd, J = 12.5, 11.2, 4.9 Hz, 1H), 3.03 (dd, J = 
15.4, 4.8 Hz, 1H), 1.74 (dd, J = 7.0, 3.6 Hz, 1H), 1.52−1.45 (m, 1H). 13C{1H} NMR (126 
MHz, CDCl3): δ 170.5, 159.3, 138.0, 129.7 (+, 2C), 129.4 (+), 128.9 (+, 2C), 126.7 (+), 
124.7 (+, 2C), 114.2 (+, 2C), 64.5 (−), 59.0 (+), 55.4 (+), 49.2 (−), 44.7 (−), 35.0, 22.5 (−). 
FTIR (NaCl, cm−1): 1647, 1512, 1248, 1177, 1032. HRMS (TOF ES): found 346.1412, 
calculated for C20H21NO3Na (M + Na) 346.1419 (2.0 ppm).
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compound was synthesized according to the typical procedure from 1-phenylcycloprop-2-
ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 2-((2-
chlorobenzyl)amino)ethan-1-ol (15d) (348 mg, 1.88 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude N-(2-chlorobenzyl)-N-(2-hydroxyethyl)-1-
phenylcycloprop-2-ene-1-carboxamide (16ad) was isolated and used at the cyclization step 
without additional purification. To this end, amide 16ad (20 mg, 0.061 mmol) was treated 
with powdered KOH (6.8 mg, 0.122 mmol). The titled product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless oil (Rf = 0.31). 
Yield 18.4 mg (0.056 mmol, 92%). 1H NMR (500 MHz, CDCl3): δ 7.41 (dd, J = 7.2, 2.1 Hz, 
1H), 7.37 (dd, J = 7.3, 1.9 Hz, 1H), 7.32 (t, J = 7.5 Hz, 2H), 7.28−7.18 (m, 3H), 7.14−7.07 
(m, 2H), 4.94 (d, J = 15.4 Hz, 1H), 4.77 (d, J = 15.4 Hz, 1H), 3.99 (ddd, J = 15.5, 12.3, 5.4 
Hz, 1H), 3.63−3.49 (m, 2H), 3.47 (dd, J = 6.2, 3.6 Hz, 1H), 3.10 (dd, J = 15.4, 4.5 Hz, 1H), 
1.75 (dd, J = 7.0, 3.6 Hz, 1H), 1.48 (t, J = 6.6 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 
170.9, 137.9, 134.9, 133.6, 130.0 (+), 129.7 (+), 129.0 (+), 129.0 (+, 2C), 127.4, 126.8, 
124.8 (+, 2C), 64.4 (−), 58.8 (+), 47.1 (−), 45.4 (−), 34.9, 22.6 (−). FTIR (NaCl, cm−1): 
1655, 1464, 1431, 1202, 1153. HRMS (TOF ES): found 328.1112, calculated for 
C19H19ClNO2 (M + H) 328.1104 (2.4 ppm).
5-(5-Bromo-2-fluorobenzyl)-7-phenyl-2-oxa-5-azabicyclo[5.1.0]-octan-6-one 
(17ae).—This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (250 mg, 1.56 mmol, 1.0 equiv) and 2-((5-
bromo-2-fluorobenzyl)amino)ethan-1-ol (15e) (581 mg, 2.34 mmol, 1.5 equiv). After 
extraction and filtration through a silica plug crude N-(5-bromo-2-fluorobenzyl)-N-(2-
hydroxyethyl)-1-phenylcycloprop-2-ene-1-carboxamide (16ae) was isolated and used at the 
cyclization step without additional purification. To this end, amide 16ae (20 mg, 0.051 
mmol) was treated with powdered KOH (5.7 mg, 0.102 mmol). The product was isolated by 
column chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless oil (Rf = 
0.31). Yield 17.4 mg (0.045 mmol, 87%). 1H NMR (500 MHz, CDCl3): δ 7.56 (dd, J = 6.6, 
2.5 Hz, 1H), 7.40−7.35 (m, 1H), 7.35−7.29 (m, 2H), 7.26−7.20 (m, 1H), 7.07 (dd, J = 5.2, 
3.3 Hz, 2H), 6.95 (t, J = 9.1 Hz, 1H), 4.87 (d, J = 15.2 Hz, 1H), 4.54 (d, J = 15.2 Hz, 1H), 
4.00 (ddd, J = 15.6, 11.4, 6.3 Hz, 1H), 3.66−3.54 (m, 2H), 3.46 (dd, J = 6.2, 3.6 Hz, 1H), 
3.13−3.03 (m, 1H), 1.74 (dd, J = 7.0, 3.6 Hz, 1H), 1.48 (t, J = 6.6 Hz, 1H). 13C{1H} NMR 
(126 MHz, CDCl3): δ 170.9, 160.1 (d, J = 246.4 Hz), 137.7, 133.4 (d, J = 4.2 Hz, +), 132.4 
(d, J = 8.2 Hz, +), 129.0 (+, 2C), 126.9 (+), 126.7 (d, J = 16.3 Hz), 124.7 (+, 2C), 117.3 (d, J 
= 23.5 Hz, +), 117.1 (d, J = 3.4 Hz), 64.2 (−), 58.8 (+), 45.7 (−),43.2 (d, J = 3.7 Hz, −), 34.8, 
22.6 (−). FTIR (NaCl, cm−1): 1643, 1478, 1252, 1113. HRMS (TOF ES): found 412.0320, 
calculated for C19H17BrFNO2Na (M + Na) 412.0324 (1.0 ppm).
5,7-Diphenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17af).—This compound was 
synthesized according to the typical procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 2-(phenylamino)ethan-1-ol (15f) (257 mg, 
1.88 mmol, 1.5 equiv). After extraction and filtration through a Silica gel plug crude N-(2-
hydroxyethyl)-N,1-diphenylcycloprop-2-ene-1-carboxamide (16af) was isolated and used at 
the cyclization step without additional purification. To this end, amide 16af (20 mg, 0.072 
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mmol) was treated with powdered KOH (8 mg, 0.144 mmol). The product was isolated by 
column chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless glass (Rf 
= 0.48). Yield 5.8 mg (0.021 mmol, 29%). 1H NMR (500 MHz, CDCl3): δ 7.44−7.39 (m, 
2H), 7.38−7.31 (m, 4H), 7.30−7.25 (m, 2H), 7.19−7.16 (m, 2H), 4.37 (ddd, J = 15.4, 12.6, 
4.9 Hz, 1H), 3.94 (ddd, J = 12.5, 11.5, 4.8 Hz, 1H), 3.76 (dd, J = 11.4, 4.9 Hz, 1H), 3.54 (dd, 
J = 6.3, 3.6 Hz, 1H), 3.47 (dd, J = 15.4, 4.7 Hz, 1H), 1.83 (dd, J = 7.1, 3.6 Hz, 1H), 1.55 (dd, 
J = 7.0, 6.3 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.4, 142.3, 137.8, 129.4 (+, 
2C), 129.0 (+, 2C), 127.1 (+), 126.9 (+), 126.4 (+, 2C), 124.7 (+, 2C), 64.9 (−), 59.3 (+), 
49.1 (−), 35.4, 22.6 (−). FTIR (NaCl, cm−1): 1663, 1493, 1398, 1215, 1157. HRMS (TOF 
ES): found 280.1336, calculated for C18H18NO2 (M + H) 280.1338 (0.7ppm).
5-(4-Methoxyphenyl)-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ag).—
This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 2-((4-
methoxyphenyl)-amino)ethan-1-ol (15g) (313 mg, 1.88 mmol, 1.5 equiv). After extraction 
and filtration through a silica plug crude N-(2-hydroxyethyl)-N-(4-methoxyphenyl)-1-
phenylcycloprop-2-ene-1-carboxamide (16ag) was used at the cyclization step as is without 
additional purification. To this end, amide 16ag (20 mg, 0.065 mmol) was treated with 
powdered KOH (7.3 mg, 0.13 mmol). The product was isolated by column chromatography 
eluting with a hexane/EtOAc mixture (1:1) as a colorless glass (Rf = 0.26). Yield 17 mg 
(0.055 mmol, 85%). 1H NMR (500 MHz, CDCl3): δ 7.35 (t, J = 7.6 Hz, 2H), 7.29−7.20 (m, 
3H), 7.16 (d, J = 7.6 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 4.34 (ddd, J = 15.4, 12.6, 4.9 Hz, 
1H), 3.92 (td, J = 12.0, 4.7 Hz, 1H), 3.81 (s, 3H), 3.73 (dd, J = 11.3, 4.9 Hz, 1H), 3.52 (dd, J 
= 6.2, 3.6 Hz, 1H), 3.38 (dd, J = 15.3, 4.7 Hz, 1H), 1.81 (dt, J = 20.0, 10.0 Hz, 1H), 1.53 (t, J 
= 6.7 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.6, 158.4, 137.9, 135.2, 129.0 (+, 
2C), 127.7 (+, 2C), 126.8 (+), 124.6 (+, 2C), 114.7 (+, 2C), 64.6 (−), 59.3 (+), 55.6 (+), 49.4 
(−), 35.3, 22.6 (−). FTIR (NaCl, cm−1): 1661, 1510, 1250, 1157. HRMS (TOF ES): found 
332.1275, calculated for C19H19NO3Na (M + Na) 332.1263 (3.6 ppm).
6-Benzyl-8-phenyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (17ah).—This 
compound was synthesized according to the typical procedure from 1-phenylcycloprop-2-
ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 3-(benzylamino)propan-1-
ol (15h) (309 mg, 1.88 mmol, 1.5 equiv). After extraction and filtration through a silica plug 
crude N-benzyl-N-(3-hydroxypropyl)-1-phenylcycloprop-2-ene-1-carboxamide (16ah) was 
used at the cyclization step as is without additional purification. To this end, amide 16ah (20 
mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product was 
isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a 
colorless solid (Rf = 0.31, mp 148−150 °C). Yield 18 mg (0.059 mmol, 90%). 1H NMR (500 
MHz, CDCl3): δ 7.29−7.17 (m, 7H), 7.15−7.11 (m, 1H), 7.04−7.00 (m, 2H), 5.33 (dd, J = 
14.7, 1.2 Hz, 1H), 4.16 (dd, J = 12.7, 5.7 Hz, 1H), 3.97 (d, J = 14.7 Hz, 1H), 3.87−3.76 (m, 
2H), 3.67 (td, J = 12.8, 3.4 Hz, 1H), 3.08 (dd, J = 15.5, 6.7 Hz, 1H), 2.04−1.92 (m, 1H), 1.79 
(dd, J = 7.0, 4.5 Hz, 1H), 1.46 (ddd, J = 15.1, 6.7, 3.3 Hz, 1H), 1.27 (t, J = 7.2 Hz, 1H). 
13C{1H} NMR (126 MHz, CDCl3): δ 170.5, 139.4, 137.7, 128.9 (+, 2C), 128.7 (+, 2C), 
128.6 (+, 2C), 127.6 (+), 126.6 (+), 124.8 (+, 2C), 73.4 (−), 68.8 (+), 48.9 (−), 45.7 (−), 35.9, 
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29.3 (−), 22.5 (−). FTIR (NaCl, cm−1): 1640, 1439, 1221, 1123. HRMS (TOF ES): found 
330.1471, calculated for C20H21NO2Na (M + Na) 330.1470 (0.3 ppm).
5-Benzyl-7-(4-fluorophenyl)-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ba).—This 
compound was synthesized according to the typical procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 
2-(benzylamino)ethan-1-ol (15a) (255 mg, 1.68 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude N-benzyl-1-(4-fluorophenyl)-N-(2-
hydroxyethyl)cycloprop-2-ene-1-carboxamide (16ba) was used at the cyclization step as is 
without additional purification. To this end, amide 16ba (20 mg, 0.064 mmol) was treated 
with powdered KOH (7.2 mg, 0.128 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless glass (Rf =0.44). 
Yield 18 mg (0.058 mmol, 90%). 1H NMR (500 MHz, CDCl3): δ 7.36−7.27 (m, 5H), 
7.12−7.04 (m, 2H), 7.00 (t, J = 8.6 Hz, 2H), 4.75−4.63 (m, 2H), 3.96−3.85 (m, 1H), 3.54 
(dd, J = 11.2, 5.1 Hz, 1H), 3.44−3.34 (m, 2H), 3.05 (dd, J = 15.4, 4.8 Hz, 1H), 1.73 (dd, J = 
6.9, 3.4 Hz, 1H), 1.41 (t, J = 6.6 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.6, 161.8 
(d, J = 245.8 Hz), 137.2, 133.7 (d, J = 3.2 Hz, +, 2C), 128.9 (+, 2C), 128.3 (+, 2C), 127.9 
(+), 126.5 (d, J = 8.0 Hz, +, 2C), 115.9 (d, J = 21.4 Hz, 2C, +), 64.4 (−), 58.5 (+), 49.9 (−), 
44.9 (−), 34.4, 22.5 (−). FTIR (NaCl, cm−1): 1649, 1512, 1230, 1153. HRMS (TOF ES): 
found 334.1207, calculated for C19H18FNO2Na (M+ Na) 334.1219 (3.6 ppm).
7-(4-Fluorophenyl)-5-methyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17bb).—
This compound was synthesized according to the typical procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 
2-(methylamino)ethan-1-ol (15b) (126 mg, 1.68 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude 1-(4-fluorophenyl)-N-(2-hydroxyethyl)-N-
methylcycloprop-2-ene-1-carboxamide (16bb) was used at the cyclization step as is without 
additional purification. To this end, amide 16bb (20 mg, 0.085 mmol) was treated with 
powdered KOH (9.5 mg, 0.17 mmol). The product was isolated by column chromatography 
eluting with EtOAc as a colorless solid (Rf = 0.51, mp 104−105 °C). Yield 17.2 mg (0.073 
mmol, 86%). 1H NMR (500 MHz, CDCl3): δ 7.05−6.96 (m, 4H), 4.04 (ddd, J = 15.3, 12.7, 
5.0 Hz, 1H), 3.86−3.76 (m, 1H), 3.69−3.61 (m, 1H), 3.38 (dd, J = 6.3, 3.5 Hz, 1H), 3.06 (s, 
3H), 3.05−3.02 (m, 1H), 1.63 (dd, J = 7.0, 3.5 Hz, 1H), 1.38 (dd, J = 6.9, 6.4 Hz, 1H). 
13C{1H} NMR (126 MHz, CDCl3): δ 170.5, 161.8 (d, J = 245.6 Hz), 133.6 (d, J = 3.1 Hz), 
126.5 (d, J = 8.0 Hz, +, 2C), 115.8 (d, J = 21.4 Hz, +, 2C), 63.3 (−), 58.4 (+), 47.5 (−), 34.4, 
34.3 (+), 22.3 (−). FTIR (NaCl, cm−1): 1649, 1512, 1203, 1165. HRMS (TOF ES): found 
236.1094, calculated for C13H15FNO2 (M + H) 236.1087 (3.0 ppm).
7-(4-Fluorophenyl)-5-(4-methoxyphenyl)-2-oxa-5-azabicyclo-[5.1.0]octan-6-one 
(17bg).—This compound was synthesized according to the typical procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 
2-((4-methoxyphenyl)amino)ethan-1-ol (15g) (282 mg, 1.68 mmol, 1.5 equiv). After 
extraction and filtration through a silica plug crude 1-(4-fluorophenyl)-N-(2-hydroxyethyl)-
N-(4-methoxyphenyl)cycloprop-2-ene (16bg) was used at the cyclization step as is without 
additional purification. To this end, amide 16bg (20 mg, 0.061 mmol) was treated with 
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powdered KOH (6.9 mg, 0.122 mmol). The product was isolated by column chromatography 
eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf 0.19, mp 132−133 °C). 
Yield 18.4 mg (0.056 mmol, 92%). 1H NMR (500 MHz, CDCl3): δ 7.23− 7.18 (m, 2H), 
7.17−7.12 (m, 2H), 7.07−7.01 (m, 2H), 6.95−6.90 (m, 2H), 4.32 (ddd, J = 15.4, 12.6, 4.9 Hz, 
1H), 3.91 (td, J = 11.9, 4.7 Hz, 1H), 3.81 (s, 3H), 3.74 (dd, J = 11.0, 5.1 Hz, 1H), 3.50 (dd, J 
= 6.2, 3.5 Hz, 1H), 3.38 (dt, J = 19.4, 9.7 Hz, 1H), 1.79 (dd, J = 7.1, 3.5 Hz, 1H), 1.45 (t, J = 
6.7 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.5, 161.9 (d, J = 245.8 Hz), 158.5, 
135.1, 133.6 (d, J = 3.1 Hz), 127.6 (+, 2C), 126.5 (d, J = 8.0 Hz, +, 2C), 115.9 (d, J = 21.5 
Hz, +, 2C), 114.7 (+, 2C), 64.6 (−), 58.9 (+), 55.7 (+), 49.3 (−), 34.8, 22.6 (−). FTIR (NaCl, 
cm−1): 1661, 1510, 1265, 1159. HRMS (TOF ES): found 350.1172, calculated for 
C19H18FNO3Na (M + Na) 350.1168 (1.1 ppm).
6-Benzyl-8-(4-fluorophenyl)-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (17bh).—
This compound was synthesized according to the typical procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 
3-(benzylamino)propan-1-ol (15h) (278 mg, 1.68 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude N-benzyl-1-(4-fluorophenyl)-N-(3-
hydroxypropyl)cycloprop-2-ene-1-carboxamide (16bh) was used at the cyclization step as is 
without additional purification. To this end, amide 16bh (20 mg, 0.061 mmol) was treated 
with powdered KOH (6.9 mg, 0.122 mmol). The product was isolated by column 
chromatography, eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf = 0.19, 
mp 132−133 °C). Yield 17.6 mg (0.054 mmol, 88%). 1H NMR (500 MHz, CDCl3): δ 
7.35−7.23 (m, 5H), 7.10−7.03 (m, 2H), 7.00−6.92 (m, 2H), 5.37 (d, J = 14.7 Hz, 1H), 4.22 
(dd, J = 12.7, 5.6 Hz, 1H), 4.01 (d, J = 14.7 Hz, 1H), 3.90−3.80 (m, 2H), 3.73 (td, J = 12.7, 
3.4 Hz, 1H), 3.14 (dd, J = 15.5, 6.7 Hz, 1H), 2.12−1.97 (m, 1H), 1.83 (dd, J = 7.0, 4.4 Hz, 
1H), 1.54 (ddd, J = 15.2, 6.7, 3.2 Hz, 1H), 1.26 (dd, J = 9.6, 4.9 Hz, 1H). 13C{1H} NMR 
(126 MHz, CDCl3): δ 170.3, 161.6 (d, J = 245.7 Hz), 137.6, 135.1 (d, J = 3.1 Hz), 128.8 (+, 
2C), 128.5 (+, 2C), 127.6 (+), 126.6 (d, J = 7.9 Hz, +, 2C), 115.8 (d, J = 21.5 Hz, +, 2C), 
73.4 (−), 68.5 (+), 48.9 (−), 45.7 (−), 35.4, 29.3 (−), 22.4 (−). FTIR (NaCl, cm−1): 1634, 
1510, 1261, 1074. HRMS (TOF ES): found 348.1385, calculated for C20H20FNO2Na (M + 
Na) 348.1376 (2.6 ppm).
6-(2-Chlorobenzyl)-8-(4-fluorophenyl)-2-oxa-6-azabicyclo[6.1.0]-nonan-7-one 
(17bi).—This compound was synthesized according to the typical procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 
3-((2-chlorobenzyl)amino)propan-1-ol (15i) (336 mg, 1.68 mmol, 1.5 equiv). After 
extraction and filtration through a silica plug crude N-(2-chlorobenzyl)-1-(4-fluorophenyl)-
N-(3-hydroxypropyl)cycloprop-2-ene-1-carboxamide (16bi) was used at the cyclization step 
as is without additional purification. To this end, amide 16bi (20 mg, 0.056 mmol) was 
treated with powdered KOH (6.2 mg, 0.112 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless glass (Rf = 0.19). 
Yield 18.4 mg (0.051 mmol, 92%). 1H NMR (500 MHz, CDCl3): δ 7.38−7.33 (m, 1H), 
7.30−7.25 (m, 1H), 7.23−7.17 (m, 2H), 7.15−7.09 (m, 2H), 7.02−6.94 (m, 2H), 5.29 (d, J = 
15.4 Hz, 1H), 4.36 (d, J = 15.4 Hz, 1H), 4.24 (dd, J = 12.8, 5.6 Hz, 1H), 3.94 (dd, J = 15.6, 
11.2 Hz, 1H), 3.90 (dd, J = 7.5, 4.4 Hz, 1H), 3.75 (tt, J = 14.4, 7.2 Hz, 1H), 3.15 (dd, J = 
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15.5, 6.6 Hz, 1H), 2.17−2.04 (m, 1H), 1.82 (dd, J = 7.0, 4.4 Hz, 1H), 1.58 (ddd, J = 15.1, 
6.5, 3.1 Hz, 1H), 1.24 (t, J = 7.2 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.6, 
161.7f (d, J = 245.7 Hz), 135.0, 134.9 (d, J = 3.2 Hz), 133.8, 129.9 (+), 129.6 (+), 128.8 (+), 
127.2 (+), 126.9 (d, J = 7.8 Hz, +, 2C), 115.8 (d, J = 21.6 Hz, +, 2C), 73.4 (−), 68.1 (+), 46.3 
(−), 46.3 (−), 35.4, 29.5 (−), 22.4 (−). FTIR (NaCl, cm−1): 1638, 1510, 1223, 1165. HRMS 
(TOF ES): found 382.1001, calculated for C20H19ClFNO2Na (M + Na) 382.0986 (3.9 ppm).
5-Benzyl-7-(2,4-dichlorophenyl)-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ca).—
This compound was synthesized according to the typical procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 mg, 0.87 mmol, 1.0 equiv) 
and 2-(benzylamino)ethan-1-ol (15a) (198 mg, 1.31 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude N-benzyl-1-(2,4-dichlorophenyl)-N-(2-
hydroxyethyl)cycloprop-2-ene-1-carboxamide (16ca) was used at the cyclization step as is 
without additional purification. To this end, amide 16ca (20 mg, 0.055 mmol) was treated 
with powdered KOH (6.2 mg, 0.11 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless oil (Rf = 0.29). 
Yield 16 mg (0.044 mmol, 80%). 1H NMR (500 MHz, CDCl3): δ 7.70 (d, J = 8.5 Hz, 1H), 
7.37 (d, J = 2.2 Hz, 1H), 7.31−7.19 (m, 6H), 4.81 (d, J = 14.8 Hz, 1H), 4.63 (ddd, J = 15.6, 
12.4, 5.4 Hz, 1H), 4.37 (d, J = 14.8 Hz, 1H), 4.01 (dd, J = 6.3, 3.2 Hz, 1H), 3.71 (dd, J = 
11.3, 5.3 Hz, 1H), 3.42−3.30 (m, 1H), 3.06 (dd, J = 15.5, 5.2 Hz, 1H), 1.72 (dd, J = 6.6, 3.2 
Hz, 1H), 1.34 (t, J = 6.4 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.2, 137.2, 134.7, 
134.0, 133.9, 133.8 (+), 130.7 (+), 128.8 (+, 2C), 128.2 (+, 2C), 127.8 (+), 127.6 (+), 64.5 
(−), 56.5 (+), 50.7 (−), 44.5 (−), 34.2, 22.4 (−). FTIR (NaCl, cm−1): 1647, 1472, 1076. 
HRMS (TOF ES): found 384.0522, calculated for C19H17Cl2NO2Na (M + Na) 384.0534 
(3.1 ppm).
7-(2,4-Dichlorophenyl)-5-methyl-2-oxa-5-azabicyclo[5.1.0]-octan-6-one (17cb).
—This compound was synthesized according to the typical procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 mg, 0.87 mmol, 1.0 equiv) 
and 2-(methylamino)ethan-1-ol (15b) (98 mg, 1.31 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude 1-(2,4-dichlorophenyl)-N-(2-hydroxyethyl)-N-
methylcycloprop-2-ene-1-carboxamide (16cb) was used at the cyclization step as is without 
additional purification. To this end, amide 16cb (20 mg, 0.07 mmol) was treated with 
powdered KOH (7.8 mg, 0.14 mmol). The product was isolated by column chromatography 
eluting with a hexane/EtOAc mixture (1:2) as a colorless solid (Rf = 0.30, mp 139−140 °C). 
Yield 15.8 mg (0.055 mmol, 79%). 1H NMR (500 MHz, CDCl3): δ 7.66 (d, J = 8.5 Hz, 1H), 
7.34 (d, J = 2.2 Hz, 1H), 7.21 (dd, J = 8.5, 2.2 Hz, 1H), 4.82−4.69 (m, 1H), 4.01 (dd, J = 6.3, 
3.2 Hz, 1H), 3.87−3.80 (m, 2H), 3.05 (ddd, J = 8.1, 5.9, 3.6 Hz, 1H), 2.97 (s, 3H), 1.62 (dd, 
J = 6.5, 3.2 Hz, 1H), 1.28 (t, J = 6.4 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.0, 
134.4, 134.0, 133.8, 133.7 (+), 130.7 (+), 127.5 (+), 63.4 (−), 56.2 (+), 46.9 (−), 35.1 (+), 
34.1, 22.3 (−). FTIR (NaCl, cm−1): 1647, 1474, 1253, 1169. HRMS (TOF ES): found 
308.0210, calculated for C13H13Cl2NO2Na (M + Na) 308.0221 (3.6 ppm).
6-Benzyl-8-(2,4-dichlorophenyl)-2-oxa-6-azabicyclo[6.1.0]-nonan-7-one (17ch).
—This compound was synthesized according to the typical procedure from 1-(2,4-
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dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 mg, 0.87 mmol, 1.0 equiv) 
and 3-(benzylamino)propan-1-ol (15h) (216 mg, 1.31 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude N-benzyl-1-(2,4-dichlorophenyl)-N-(3-
hydroxypropyl)cycloprop-2-ene-1-carboxamide (16ch) was used at the cyclization step as is 
without additional purification. To this end, amide 16ch (20 mg, 0.053 mmol) was treated 
with powdered KOH (6 mg, 0.106 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless solid (Rf = 0.37, 
mp 151−153 °C). Yield 17 mg (0.045 mmol, 85%). 1H NMR (500 MHz, CDCl3): δ 7.70 (d, 
J = 8.5 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.26−7.18 (m, 4H), 7.13− 7.03 (m, 2H), 5.23 (d, J 
= 15.0 Hz, 1H), 4.45−4.35 (m, 2H), 4.19 (dt, J = 25.4, 12.7 Hz, 1H), 4.05−3.92 (m, 2H), 
3.07 (dd, J = 15.5, 6.6 Hz, 1H), 2.06−1.95 (m, 1H), 1.94 (dd, J = 6.7, 4.3 Hz, 1H), 1.94 (dd, 
J = 6.7, 4.3 Hz, 1H), 1.16−1.13 (m, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 169.9, 137.5, 
134.7, 134.6, 133.9, 133.5 (+), 130.8 (+), 128.7 (+, 2C), 128.0 (+, 2C), 127.6 (+), 127.4 (+), 
72.6 (−), 66.2 (+), 49.6 (−), 45.5 (−), 35.7, 29.8 (−), 21.6 (−). FTIR (NaCl, cm−1): 1643, 
1473, 1219, 1105. HRMS (TOF ES): found 398.0709, calculated for C20H19Cl2NO2Na (M 
+ Na) 398.0691 (4.5 ppm).
(+)-(1S,4S,7S)-4-Benzyl-5-methyl-7-phenyl-2-oxa-5-azabicyclo-[5.1.0]octan-6-
one (19aa).—This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and (S)-2-
(methylamino)-3-phenylpropan-1-ol (30a) (309 mg, 1.88 mmol, 1.5 equiv). After extraction 
and filtration through a silica plug crude (S)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-
methyl-1-phenylcycloprop-2-ene-1-carboxamide (18aa) was used at the cyclization step as 
is without additional purification. To this end, amide 18aa (20 mg, 0.065 mmol) was treated 
with powdered KOH (7.3 mg, 0.13 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless oil (Rf = 0.38). 
Yield 18.2 mg (0.059 mmol, 91%). [α]D20 +45.3 (c = 0.8, CHCl3). 1H NMR (500 MHz, 
CDCl3): δ 7.33−7.23 (m, 6H), 7.03−6.97 (m, 4H), 4.66 (dddd, J = 10.8, 9.6, 5.9, 4.9 Hz, 
1H), 3.66−3.52 (m, 2H), 3.42 (dd, J = 6.2, 3.5 Hz, 1H), 2.93 (s, 3H), 2.91 (dd, J = 15.0, 9.6 
Hz, 1H), 2.80 (dd, J = 14.9, 5.8 Hz, 1H), 1.71 (dd, J = 7.1, 3.6 Hz, 1H), 1.52 (dd, J = 7.1, 6.3 
Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.8, 137.7, 136.7, 128.8 (+, 2C), 128.8 (+, 
2C), 128.6 (+, 2C), 127.0 (+), 126.9 (+), 124.7 (+, 2C), 67.6 (−), 59.8 (+), 54.8 (+), 35.1, 
34.1 (−), 27.3 (+), 23.0 (−). FTIR (NaCl, cm−1): 1649, 1497, 1200. HRMS (TOF ES): found 
330.1480, calculated for C20H21NO2Na (M + Na) 330.1470 (3.0 ppm).
(+)-(1S,4S,7S)-4,5-Dibenzyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]-octan-6-one 
(19ab).—This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and (S)-2-
(benzylamino)-3-phenylpropan-1-ol (30b) (452 mg, 1.88 mmol, 1.5 equiv). After extraction 
and filtration through a silica plug crude (S)-N-benzyl-N-(1-hydroxy-3-phenylpropan-2-
yl)-1-phenylcycloprop-2-ene-1-carboxamide (18ab) was used at the cyclization step as is 
without additional purification. To this end, amide 18ab (20 mg, 0.052 mmol) was treated 
with powdered KOH (5.8 mg, 0.104 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless glass (Rf = 0.31). 
Yield 18.6 mg (0.048 mmol, 93%). [α]D20 +67.0 (c = 1.1, CHCl3). 1H NMR (500 MHz, 
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CDCl3): δ 7.39−7.22 (m, 11H), 7.13−7.09 (m, 2H), 7.03−6.98 (m, 2H), 5.44 (d, J = 15.8 Hz, 
1H), 4.76 (dddd, J = 11.7, 9.1, 6.1, 4.5 Hz, 1H), 4.06 (d, J = 15.7 Hz, 1H), 3.50 (dd, J = 6.3, 
3.6 Hz, 1H), 3.44 (dd, J = 11.1, 4.5 Hz, 1H), 3.07 (t, J = 11.4 Hz, 1H), 2.98 (dd, J = 15.2, 9.2 
Hz, 1H), 2.69 (dd, J = 15.2, 6.1 Hz, 1H), 1.90 (dd, J = 7.1, 3.5 Hz, 1H), 1.58 (dd, J = 7.1, 6.3 
Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 172.0, 138.9, 137.7, 136.9, 128.9 (+, 2C), 
128.9 (+, 2C), 128.7 (+, 2C), 128.3 (+, 2C), 127.5 (+, 2C), 127.4 (+), 127.0 (+), 127.0 (+), 
124.9 (+, 2C), 69.5 (−), 59.9 (+), 54.8 (+), 44.8 (−), 35.2, 33.5 (−), 23.3 (−). FTIR (NaCl, cm
−1): 1649, 1497, 1207, 1055. HRMS (TOF ES): found 406.1770, calculated for 
C26H25NO2Na (M + Na) 406.1783 (3.2 ppm).
(+)-(1S,4S,7S)-5-Benzyl-4-isobutyl-7-phenyl-2-oxa-5-azabicyclo-[5.1.0]octan-6-
one (19ad).—This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and (S)-2-
(benzylamino)-4-methylpentan-1-ol (30d) (388 mg, 1.88 mmol, 1.5 equiv). After extraction 
and filtration through a silica plug crude (S)-N-benzyl-N-(1-hydroxy-4-methylpentan-2-
yl)-1-phenylcycloprop-2-ene-1-carboxamide (18ad) was used at the cyclization step as is 
without additional purification. To this end, amide 18ad (20 mg, 0.057 mmol) was treated 
with powdered KOH (6.4 mg, 0.114 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf = 0.38, 
mp 117−118 °C). Yield 18.8 mg (0.054 mmol, 94%). [α]D20 +83.4 (c = 0.8, CHCl3). 1H 
NMR (500 MHz, CDCl3): δ 7.35−7.20 (m, 8H), 7.12−7.07 (m, 2H), 5.39 (d, J = 15.7 Hz, 
1H), 4.37−4.25 (m, 1H), 4.12 (d, J = 15.5 Hz, 1H), 3.46 (dd, J = 6.2, 3.6 Hz, 1H), 3.35 (dd, J 
= 11.1, 4.5 Hz, 1H), 2.99− 2.87 (m, 1H), 1.86 (dd, J = 7.1, 3.5 Hz, 1H), 1.65 (ddd, J = 14.2, 
9.7, 4.4 Hz, 1H), 1.57 (dd, J = 7.1, 6.3 Hz, 1H), 1.55−1.46 (m, 1H), 0.98 (ddd, J = 14.3, 9.0, 
4.4 Hz, 1H), 0.82 (d, J = 6.7 Hz, 3H), 0.63 (d, J = 6.5 Hz, 3H). 13C{1H} NMR (126 MHz, 
CDCl3): δ 172.4, 138.9, 137.9, 128.9 (+, 2C), 128.6 (+, 2C), 127.7 (+, 2C), 127.3 (+), 126.8 
(+), 124.6 (+, 2C), 69.6 (−), 60.0 (+), 52.9 (+), 44.7 (−), 36.3 (−), 35.2, 25.3 (+), 23.2 (−), 
23.1 (+), 21.7 (+). FTIR (NaCl, cm−1): 1647, 1497, 1219, 1029. HRMS (TOF ES): found 
372.1926, calculated for C23H27NO2Na (M + Na) 372.1939 (3.5 ppm).
(+)-(1S,4S,7S)-4-Benzyl-7-(4-fluorophenyl)-5-methyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19ba).—This compound was synthesized according to 
the typical procedure from 1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (14b) (200 
mg, 1.12 mmol, 1.0 equiv) and (S)-2-(methylamino)-3-phenylpropan-1-ol (30a) (278 mg, 
1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude (S)-1-(4-
fluorophenyl)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-
carboxamide (18ba) was used at the cyclization step as is without additional purification. To 
this end, amide 18ba (20 mg, 0.061 mmol) was treated with powdered KOH (6.8 mg, 0.122 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless oil (Rf = 0.1). Yield 19.2 mg (0.059 mmol, 96%). [α]D20 +41.0 
(c = 0.9, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.28−7.22 (m, 3H), 7.04−6.92 (m, 6H), 
4.70−4.53 (m, 1H), 3.68−3.51 (m, 2H), 3.39 (dd, J = 6.3, 3.5 Hz, 1H), 2.98−2.89 (m,1H), 
2.92 (s, 3H), 2.80 (dd, J = 14.9, 5.8 Hz, 1H), 1.69 (dd, J = 7.2, 3.5 Hz, 1H), 1.45 (dd, J = 7.2, 
6.3 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.5, 161.9 (d, J = 245.6 Hz), 136.7, 
133.4 (d, J = 3.1 Hz), 128.8 (+, 2C), 128.5 (+, 2C), 127.1 (+), 126.4 (d, J = 7.9 Hz, +, 2C), 
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115.7 (d, J = 21.4 Hz, +, 2C), 67.5 (−), 59.5 (+), 55.1 (+), 34.6, 34.1 (−), 27.3 (+), 23.0 (−). 
FTIR (NaCl, cm−1): 1647, 1510, 1049. HRMS (TOF ES): found 348.1390, calculated for 
C20H20FNO2Na (M + Na) 348.1376 (4.0 ppm).
(+)-(1S,4S,7S)-4,5-Dibenzyl-7-(4-fluorophenyl)-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19bb).—This compound was synthesized according to 
the typical procedure from 1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (14b) (200 
mg, 1.12 mmol, 1.0 equiv) and (S)-2-(benzylamino)-3-phenylpropan-1-ol (30b) (406 mg, 
1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude (S)-N-
benzyl-1-(4-fluorophenyl)-N-(1-hydroxy-3-phenylpropan-2-yl)cycloprop-2-ene-1-
carboxamide (18bb) was used at the cyclization step as is without additional purification. To 
this end, amide 18bb (20 mg, 0.05 mmol) was treated with powdered KOH (5.6 mg, 0.1 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless glass (Rf = 0.31). Yield 18 mg (0.045 mmol, 90%). [α]D20 +53.0 
(c = 0.90, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.34−7.30 (m, 4H), 7.28−7.22 (m, 4H), 
7.11−7.02 (m, 4H), 6.99 (dd, J = 7.4, 2.1 Hz, 2H), 5.41 (d, J = 15.7 Hz, 1H), 4.71 (dddd, J = 
11.8, 9.0, 6.2, 4.5 Hz, 1H), 4.06 (d, J = 15.7 Hz, 1H), 3.48 (dd, J = 6.4, 3.6 Hz, 1H), 3.44 
(dd, J = 11.2, 4.6 Hz, 1H), 3.07 (t, J = 11.4 Hz, 1H), 2.99 (dd, J = 15.1, 9.0 Hz, 1H), 2.69 
(dd, J = 15.1, 6.2 Hz, 1H), 1.87 (dd, J = 7.2, 3.5 Hz, 1H), 1.50 (dd, J = 7.1, 6.3 Hz, 1H). 
13C{1H} NMR (126 MHz, CDCl3): δ 171.9, 161.9 (d, J = 245.8 Hz), 138.8, 136.9, 133.5 (d, 
J = 3.2 Hz), 129.0 (+, 2C), 128.7 (+, 2C), 128.3 (+, 2C), 127.5 (+), 127.4 (+, 2C), 127.1 (+), 
126.6 (d, J = 7.9 Hz, +, 2C), 115.8 (d, J = 21.7 Hz, +, 2C), 69.5 (−), 59.5 (+), 55.0 (+), 44.9 
(−), 34.7, 33.6 (−), 23.3 (−). FTIR (NaCl, cm−1): 1649, 1512, 1233, 1165. HRMS (TOF ES): 
found 424.1707, calculated for C26H24FNO2Na (M + Na) 424.1689 (4.2 ppm).
(−)-(1R,4R,7R)-5-Benzyl-7-(4-fluorophenyl)-4-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19bc).—This compound was synthesized according to 
the typical procedure from 1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (14b) (200 
mg, 1.12 mmol, 1.0 equiv) and (R)-2-(benzylamino)-2-phenylethan-1-ol (30c) (383 mg, 1.68 
mmol, 1.5 equiv). After extraction the (R)-N-benzyl-1-(4-fluorophenyl)-N-(2-hydroxy-1-
phenylethyl)cycloprop-2-ene-1-carbox-amide (18bc) was isolated by column 
chromatography eluting with a dichloromethane/EtOAc mixture (3:1) as a mixture of 
rotamers in a ratio of 2.2:1 as a colorless solid (Rf = 0.33, mp 158−159 °C). Yield 146.7 mg 
(0.38 mmol, 34%). [α]D20−28.3 (c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3): δ 
[7.44−7.20 (m), Σ8H], [7.10−7.06 (m), 7.01−6.92 (m), 6.80 (br. m), Σ6H], [5.48−5.42 (m), 
5.22 (dd, J = 8.4, 4.6 Hz), Σ1H], [5.11 (d, J = 15.1 Hz), 4.42 (d, J = 16.9 Hz), 4.20 (d, J = 
16.9 Hz), 3.87 (d, J = 15.0 Hz), Σ2H], [4.15−4.08 (m), 4.06−4.00 (m), 3.81−3.65 (br. m), 
3.63−3.55 (br. m), Σ2H], [1.72 (br.s), 1.40 (br. s), Σ1H]. 13C{1H} NMR (126 MHz, CDCl3): 
δ Major rotamer: 176.9, 161.8 (d, J = 245.4 Hz), 138.4 (d, J = 2.7 Hz), 137.7, 137.0, 128.8 
(+, 4C), 128.5 (+, 2C), 128.2 (+),127.8 (d, J = 7.8 Hz, +, 2C), 127. Six (+), 126.8 (+, 2C), 
115.5 (d, J = 21.2 Hz, +, 2C), 110.2 (+), 109.8 (+), 63.9 (−), 63.1 (+), 50.6 (−), 32.6. Minor 
rotamer: 176.1, 161.9 (d, J = 246.1 Hz), 139.3, 139.0 (d, J = 2.6 Hz), 136.6, 128.9 (+, 4C), 
128.1 (+), 127.8 (+, 2C), 127.5 (+), 128.4 (d, J = 7.9 Hz, +, 2C), 127.6 (+, 2C), 115.5 (d, J = 
21.2 Hz, +, 2C), 111.7 (+), 110.4 (+), 62.5 (+), 62.4 (−), 45.7 (−), 29.8. FTIR (NaCl, cm−1): 
3366 (br), 1605, 1492, 1231, 1159. HRMS (TOF ES): found 410.1512, calculated for 
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C25H22FNO2Na (M + Na) 410.1532 (4.9 ppm). To this end, amide 18bc (20 mg, 0.052 
mmol) was treated with powdered KOH (5.8 mg, 0.104 mmol). The product was isolated by 
column chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf 
= 0.4, mp 192−194 °C). Yield 17.8 mg (0.046 mmol, 89%). [α]D20−82.6 (c = 0.8, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.37−7.31 (m, 1H), 7.32−7.26 (m, 2H), 7.19−7.16 (m, 5H), 
7.12−7.06 (m, 2H), 6.96−6.89 (m, 4H), 5.46 (dd, J = 11.7, 5.1 Hz, 1H), 5.04 (d, J = 15.3 Hz, 
1H), 3.82−3.71 (m, 3H), 3.52 (dd, J = 6.3, 3.5 Hz, 1H), 1.92 (dd, J = 7.2, 3.5 Hz, 1H), 1.59 
(dd, J = 7.2, 6.3 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.1, 161.9 (d, J = 245.8 
Hz), 138.3, 133.9 (d, J = 3.0 Hz), 132.6, 129.7 (+, 2C), 129.3 (+), 128.9 (+, 2C), 128.2 (+, 
2C), 127.7 (+, 2C), 127.1 (+), 126.3 (d, J = 7.9 Hz, +, 2C), 116.1 (d, J = 21.5 Hz, +, 2C), 
67.2 (−), 59.9 (+), 58.5 (+), 45.6 (−), 34.7, 23.2 (−). FTIR (NaCl, cm−1): 1651, 1510, 1223, 
1165. HRMS (TOF ES): found 410.1539, calculated for C25H22FNO2Na (M + Na) 
410.1532 (1.7 ppm).
(+)-(1S,4S,7S)-5-Benzyl-7-(4-fluorophenyl)-4-isobutyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19bd).—This compound was synthesized according to a 
typical procedure from 1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (14b) (200 
mg, 1.12 mmol, 1.0 equiv) and (S)-2-(benzylamino)-4-methylpentan-1-ol (30d) (349 mg, 
1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude (S)-N-
benzyl-1-(4-fluorophenyl)-N-(1-hydroxy-4-methylpentan-2-yl) cycloprop-2-ene-1-
carboxamide (18bd) was used at the cyclization step as is without additional purification. To 
this end, amide 18bd (20 mg, 0.054 mmol) was treated with powdered KOH (6.1 mg, 0.108 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless solid (Rf = 0.35, mp 139−141 °C). Yield 18.6 mg (0.05 mmol, 
93%). [α]D20 +79.3 (c = 0.7, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.31−7.21 (m, 5H), 
7.12−7.06 (m, 2H), 7.05−6.99 (m, 2H), 5.37 (d, J = 15.5 Hz, 1H), 4.29 (ddt, J = 11.9, 9.2, 
4.5 Hz, 1H), 4.10 (d, J = 15.5 Hz, 1H), 3.45 (dd, J = 6.3, 3.5 Hz, 1H), 3.36 (dd, J = 11.0, 4.5 
Hz, 1H), 2.99−2.89 (m, 1H), 1.84 (dd, J = 7.1, 3.5 Hz, 1H), 1.65 (ddd, J = 14.2, 9.4, 4.6 Hz, 
1H), 1.56−1.46 (m, 1H), 1.49 (dd, J = 7.1, 6.3 Hz, 1H), 1.00 (ddd, J = 14.4, 9.0, 4.5 Hz, 1H), 
0.83 (d, J = 6.6 Hz, 3H), 0.65 (d, J = 6.5 Hz, 3H). 13C{1H} NMR (126 MHz, CDCl3): δ 
172.2, 161.8 (d, J = 245.6 Hz), 138.7, 133.7 (d, J = 3.2 Hz), 128.6 (+, 2C), 127.7 (+, 2C), 
127.4 (+), 126.4 (d, J = 7.9 Hz, +, 2C), 115.8 (d, J = 21.5 Hz, +, 2C), 69.6 (−), 59.5 (+), 52.9 
(+), 44.7 (−), 36.2 (−), 34.7, 25.3 (+), 23.3 (−), 23.0 (+), 21.8 (+). FTIR (NaCl, cm−1): 1649, 
1496, 1207, 1055. HRMS (TOF ES): found 368.2028, calculated for C23H27FNO2 (M + H) 
368.2026 (0.5 ppm).
(+)-(1S,4S,7S)-4-Benzyl-7-(2,4-dichlorophenyl)-5-methyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19ca).—This compound was synthesized according to 
the typical procedure from 1-(2,4-dichlorophenyl)-cycloprop-2-ene-1-carboxylic acid (14c) 
(200 mg, 0.87 mmol, 1.0 equiv) and (S)-2-(methylamino)-3-phenylpropan-1-ol (30a) (216 
mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude (S)-1-
(2,4-dichlorophenyl)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-
carboxamide (18ca) was used at the cyclization step as is without additional purification. To 
this end, amide 18ca (20 mg, 0.053 mmol) was treated with powdered KOH (5.9 mg, 0.106 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
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mixture (1:1) as a colorless oil (Rf = 0.5). Yield 16.8 mg (0.045 mmol, 84%). [α]D20 +36.5 
(c = 0.7, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.63 (d, J = 8.5 Hz, 1H), 7.36 (d, J = 2.2 
Hz, 1H), 7.31−7.19 (m, 4H), 7.15−7.10 (m, 2H), 5.15 (ddt, J = 11.9, 7.7, 3.8 Hz, 1H), 4.07 
(dd, J = 6.3, 3.2 Hz, 1H), 3.75 (dd, J = 11.4, 4.4 Hz, 1H), 3.54 (t, J = 11.3 Hz, 1H), 3.04 (dd, 
J = 14.3, 7.7 Hz, 1H), 2.88 (s, 3H), 2.83 (dd, J = 14.3, 7.7 Hz, 1H), 1.66 (dd, J = 6.7, 3.2 Hz, 
1H), 1.39 (t, J = 6.5 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.0, 136.9, 133.9, 
133.9, 133.7 (+), 133.5, 130.7 (+), 128.9 (+, 2C), 128.7 (+, 2C), 127.6 (+), 127.1 (+), 67.5 
(−), 56.9 (+), 54.4 (+), 35.0 (−), 34.6, 28.2 (+), 22.9 (−). FTIR (NaCl, cm−1): 1645, 1474, 
1200, 1152. HRMS (TOF ES): found 398.0704, calculated for C20H19Cl2NO2Na (M + Na) 
398.0691 (3.3 ppm).
(+)-(1S,4S,7S)-4,5-Dibenzyl-7-(2,4-dichlorophenyl)-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19cb).—This compound was synthesized according to 
the typical procedure from 1-(2,4-dichlorophenyl)-cycloprop-2-ene-1-carboxylic acid (14c) 
(200 mg, 0.87 mmol, 1.0 equiv) and (S)-2-(benzylamino)-3-phenylpropan-1-ol (30b) (316 
mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude (S)-N-
benzyl-1-(2,4-dichlorophenyl)-N-(1-hydroxy-3-phenylpropan-2-yl)cycloprop-2-ene-1-
carboxamide (18cb) was used at the cyclization step as is without additional purification. To 
this end, amide 18cb (20 mg, 0.044 mmol) was treated with powdered KOH (4.9 mg, 0.088 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless oil (Rf = 0.44). Yield 17.4 mg (0.038 mmol, 87%). [α]D20 +56.6 
(c = 0.7, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.5 Hz, 1H), 7.40 (d, J = 2.2 
Hz, 1H), 7.34−7.19 (m, 9H), 7.13−7.07 (m, 2H), 5.26 (dt, J = 7.9, 4.0 Hz, 1H), 5.20 (d, J = 
15.8 Hz, 1H), 4.16 (d, J = 15.7 Hz, 1H), 4.10 (dd, J = 6.3, 3.3 Hz, 1H), 3.64 (dd, J = 11.3, 
4.5 Hz, 1H), 3.13 (t, J = 11.3 Hz, 1H), 3.08 (dd, J = 14.4, 7.3 Hz, 1H), 2.76 (dd, J = 14.4, 7.9 
Hz, 1H), 1.82 (dd, J = 6.6, 3.2 Hz, 1H), 1.43 (t, J = 6.5 Hz, 1H). 13C{1H} NMR (126 MHz, 
CDCl3): δ 171.5, 138.7, 137.0, 134.1, 134.0 (+), 133.7, 130.7 (+), 129.0 (+, 2C), 128.7 (+, 
2C), 128.5 (+, 2C), 127.7 (+), 127.4 (+, 2C), 127.4 (+), 127.1 (+), 69.2 (−), 57.3 (+), 54.4 
(+), 45.6 (−), 34.6, 34.5 (−), 23.3 (−). FTIR (NaCl, cm−1): 1647, 1473, 1244, 1030. HRMS 
(TOF ES): found 452.1195, calculated for C26H24Cl2NO2 (M + H) 452.1184 (2.4 ppm).
(+)-(1S,4S,7S)-5-Benzyl-7-(2,4-dichlorophenyl)-4-isobutyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (19cd).—This compound was synthesized according to 
the typical procedure from 1-(2,4-dichlorophenyl)-cycloprop-2-ene-1-carboxylic acid (14c) 
(200 mg, 0.87 mmol, 1.0 equiv) and (S)-2-(benzylamino)-4-methylpentan-1-ol (30d) (272 
mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude (S)-N-
benzyl-1-(2,4-dichlorophenyl)-N-(1-hydroxy-4-methylpentan-2-yl)cycloprop-2-ene-1-
carboxamide (18cd) was used at the cyclization step as is without additional purification. To 
this end, amide 18cd (20 mg, 0.048 mmol) was treated with powdered KOH (5.4 mg, 0.096 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless solid (Rf = 0.53, mp 144−146 °C). Yield 18 mg (0.043 mmol, 
90%). [α]D20 +77.6 (c = 0.8, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.72 (d, J = 8.5 Hz, 
1H), 7.37 (d, J = 2.2 Hz, 1H), 7.28−7.19 (m, 6H), 5.28 (d, J = 15.6 Hz, 1H), 4.87 (ddt, J = 
11.7, 9.5, 4.8 Hz, 1H), 4.15 (dd, J = 6.3, 3.2 Hz, 1H), 4.02 (d, J = 15.6 Hz, 1H), 3.60 (dd, J = 
11.2, 4.7 Hz, 1H), 2.97 (t, J = 11.4 Hz, 1H), 1.81 (dd, J = 6.7, 3.2 Hz, 1H), 1.66 (ddd, J = 
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14.1, 9.1, 5.0 Hz, 1H), 1.62−1.50 (m, 1H), 1.41 (t, J = 6.5 Hz, 1H), 1.12 (ddd, J = 13.8, 8.6, 
5.0 Hz, 1H), 0.91 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.4 Hz, 3H). 13C{1H} NMR (126 MHz, 
CDCl3): δ 171.8, 138.7, 134.2, 133.9, 133.6, 133.6 (+), 130.8 (+), 128.6 (+, 2C), 127.5 (+, 
3C), 127.3 (+), 69.6 (−), 57.2 (+), 52.1 (+), 45.2 (−), 36.7 (−), 34.4, 25.4 (+), 23.2 (−), 23.2 
(+), 22.3 (+). FTIR (NaCl, cm−1): 1647, 1473, 1217, 1005. HRMS (TOF ES): found 
440.1143, calculated for C23H25Cl2NO2Na (M + Na) 440.1160 (3.9 ppm).
(1S,3R,7S)- and (1R,3R,7R)-5-Benzyl-7-(4-fluorophenyl)-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (22b and 23b).—These compounds were synthesized 
according to the typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic 
acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and (R)-2-(benzylamino)-1-phenylethan-1-ol 
(31) (383 mg, 1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug 
crude (R)-N-benzyl-1-(4-fluorophenyl)-N-(2-hydroxy-2-phenylethyl)cycloprop-2-ene-1-
carboxamide (21b) was used at the cyclization step as is without additional purification. To 
this end, amide 21b (20 mg, 0.052 mmol) was treated with powdered KOH (5.8 mg, 0.104 
mmol). The reaction mixture was vigorously stirred at 50 °C for 48 h. The product was 
isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) as a mixture 
of diastereomers in a ratio of 4:1 as a colorless oil (Rf = 0.30). Yield 18.8 mg (0.049 mmol, 
94%). 1H NMR (500 MHz, CDCl3): δ Major diastereomer: 7.43−7.19 (m, 10H), 7.12−7.03 
(m, 2H), 7.03−6.95 (m, 2H), 4.79 (dd, J = 32.0, 14.8 Hz, 2H), 4.54 (dd, J = 11.6, 4.4 Hz, 
1H), 4.10 (dd, J = 15.2, 11.5 Hz, 1H), 3.58 (dd, J = 6.3, 3.5 Hz, 1H), 3.47 (dd, J = 15.3, 4.5 
Hz, 1H), 1.79 (dd, J = 6.9, 3.5 Hz, 1H), 1.42 (t, J = 6.6 Hz, 1H). Minor diastereomer: 
7.43−7.19 (m, 10H), 7.12−7.03 (m, 2H), 7.03−6.95 (m, 1H), 6.92−6.90 (m, 1H), 5.37 (d, J = 
14.8 Hz, 1H), 4.85 (d, J = 4.7 Hz, 1H), 4.15 (dd, J = 15.0, 4.6 Hz, 1H), 3.71 (dd, J = 6.2, 3.5 
Hz, 1H), 3.16 (d, J = 15.3 Hz, 1H), 2.82 (d, J = 14.8 Hz, 1H), 1.95 (dd, J = 7.0, 3.4 Hz, 1H), 
1.53 (dd, J = 7.1, 6.3 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ Major diastereomer: 
170.6, 161.8 (d, J = 245.8 Hz), 137.5, 137.1, 133.5 (d, J = 3.2 Hz), 129.0 (+, 2C), 129.0 (+, 
2C), 128.4 (+), 128.4 (+, 2C), 128.0 (+), 126.7 (d,z J = 8.1 Hz, +, 2C), 126.4 (+, 2C), 115.9 
(d, J = 21.6 Hz, +, 2C), 74.3 (+), 55.1 (+), 50.2 (−), 48.5 (−), 34.5, 22.4 (−). Minor 
diastereomer: 170.5, 161.8 (d, J = 246.1 Hz), 140.0, 137.0, 133.7 (d, J = 3.2 Hz), 128.7 (+, 
2C), 128.7 (+, 2C), 128.3 (+, 2C), 128.2 (+), 127.7 (+), 126.5 (d, J = 7.9 Hz, +, 2C), 125.8 
(+, 2C), 115.9 (d, J = 21.4 Hz, +, 2C), 75.8 (+), 59.1 (+), 50.7 (−), 50.5 (−), 34.5, 22.7 (−). 
HRMS (TOF ES): found 410.1529, calculated for C25H22FNO2Na (M + Na) 410.1532 (0.7 
ppm).
(−)-(1S,3S,4S,7S)-4,5-Dimethyl-3,7-diphenyl-2-oxa-5-azabicyclo-[5.1.0]octan-6-
one (25a).—This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and (1S,
2S)-(+)-pseudoephedrine hydrochloride (32) (378 mg, 1.88 mmol, 1.5 equiv). After 
extraction and filtration through a silica plug crude N-((1S,2S)-1-hydroxy-1-
phenylpropan-2-yl)-N-methyl-1-phenylcyclo-prop-2-ene-1-carboxamide (24a) was used at 
the cyclization step as is without additional purification. To this end, amide 24a (20 mg, 
0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product was 
isolated by column chromatography eluting with a hexane/EtOAc mixture (3:2) as a 
colorless glass (Rf = 0.28). Yield 17.2 mg (0.056 mmol, 86%). [α]D20 −55.3 (c = 0.80, 
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CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.42−7.32 (m, 5H), 7.29−7.24 (m, 3H), 7.14−7.07 
(m, 2H), 4.70 (dq, J = 10.8, 6.9 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 3.68 (dd, J = 6.4, 3.6 Hz, 
1H), 3.08 (s, 3H), 1.71 (dd, J = 6.8, 3.5 Hz, 1H), 1.44 (t, J = 6.7 Hz, 1H), 1.12 (d, J = 7.0 Hz, 
3H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.5, 138.2, 136.6, 129.2 (+, 2C), 129.1 (+, 2C), 
129.1 (+), 128.5 (+, 2C), 126.8 (+), 124.5 (+, 2C), 80.1 (+), 55.7 (+), 51.5 (+), 35.1, 27.6 (+), 
23.4 (−), 15.1 (+). FTIR (NaCl, cm−1): 1649, 1495, 1152. HRMS (TOF ES): found 
330.1469, calculated for C20H21NO2Na (M + Na) 330.1470 (0.3 ppm).
(+)-(1R,3R,4R,7R)-4,5-Dimethyl-3,7-diphenyl-2-oxa-5-azabicyclo-[5.1.0]octan-6-
one (ent-25a).—This compound was synthesized according to the typical procedure from 
1-phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and (1R,
2R)-(−)-pseudoephedrine hydrochloride (ent-32) (378 mg, 1.88 mmol, 1.5 equiv). After 
extraction and filtration through a silica plug crude N-((1R,2R)-1-hydroxy-1-
phenylpropan-2-yl)-N-methyl-1-phenylcyclo-prop-2-ene-1-carboxamide (ent-24a) was used 
at the cyclization step as is without additional purification. To this end, amide ent-24a (20 
mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product was 
isolated by column chromatography eluting with a hexane/EtOAc mixture (3:2) as a 
colorless glass (Rf = 0.28). [α]D20 +55.9 (c = 0.80, CHCl3). Yield 17.6 mg (0.057 mmol, 
88%). 1H NMR (500 MHz, CDCl3): δ 7.41−7.32 (m, 5H), 7.30−7.25 (m, 3H), 7.14−7.10 
(m, 2H), 4.70 (dq, J = 10.8, 7.0 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 3.68 (dd, J = 6.4, 3.5 Hz, 
1H), 3.08 (s, 3H), 1.71 (dd, J = 6.9, 3.5 Hz, 1H), 1.44 (t, J = 6.7 Hz, 1H), 1.12 (d, J = 7.0 Hz, 
3H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.5, 138.2, 136.6, 129.2 (+, 2C), 129.1 (+, 2C), 
129.1 (+), 128.5 (+, 2C), 126.8 (+), 124.5 (+, 2C), 80.1 (+), 55.7 (+), 51.5 (+), 35.1, 27.6 (+), 
23.4 (−), 15.1 (+). FTIR (NaCl, cm−1): 1645, 1495, 1152. HRMS (TOF ES): found 
330.1467, calculated for C20H21NO2Na (M + Na) 330.1470 (0.9 ppm).
(−)-(1S,3S,4S,7S)-7-(4-Fluorophenyl)-4,5-dimethyl-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (25b).—This compound was synthesized according to the 
typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 
1.12 mmol, 1.0 equiv) and (1S,2S)-(+)-pseudoephedrine hydrochloride (32) (340 mg, 1.68 
mmol, 1.5 equiv). After extraction and filtration through a silica plug crude 1-(4-
fluorophenyl)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-
carboxamide (24b) was used at the cyclization step as is without additional purification. To 
this end, amide 24b (20 mg, 0.061 mmol) was treated with powdered KOH (6.8 mg, 0.122 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (3:1) as a colorless solid (Rf = 0.60, mp 73−75 °C). [α]D20 −49.5 (c = 0.80, CHCl3). 
Yield 18.6 mg (0.057 mmol, 93%). 1H NMR (500 MHz, CDCl3): δ 7.39 (dd, J = 5.7, 1.6 Hz, 
3H), 7.26 (s, 2H), 7.12−7.03 (m, 4H), 4.67 (dq, J = 10.8, 6.9 Hz, 1H), 4.38 (d, J = 10.8 Hz, 
1H), 3.64 (dd, J = 6.5, 3.5 Hz, 1H), 3.07 (s, 3H), 1.70 (dd, J = 6.9, 3.5 Hz, 1H), 1.38 (t, J = 
6.7 Hz, 1H), 1.14 (d, J = 7.0 Hz, 3H). 13C{1H} NMR (126 MHz, CDCl3): δ 171.4, 161.8 (d, 
J = 245.6 Hz), 136.4, 133.9 (d, J = 3.0 Hz), 129.2 (+, 2C), 129.1 (+), 128.4 (+, 2C), 126.2 (d, 
J = 8.0 Hz, +, 2C), 116.1 (d, J = 21.4 Hz, +, 2C), 80.0 (+), 55.4 (+), 51.5 (+), 34.6, 27.6 (+), 
23.3 (−), 15.1 (+). FTIR (NaCl, cm−1): 1648, 1510, 1232, 1151. HRMS (TOF ES): found 
348.1383, calculated for C20H20FNO2Na (M + Na) 348.1376 (2.0 ppm).
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azabicyclo[5.1.0]octan-6-one (ent-25b).—This compound was synthesized according 
to the typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) 
(200 mg, 1.12 mmol, 1.0 equiv) and (1R,2R)-(−)-pseudoephedrine hydrochloride (ent-32) 
(340 mg, 1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude 1-
(4-fluorophenyl)-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-
carboxamide (ent-24b) was used at the cyclization step as is without additional purification. 
To this end, amide ent-24b (20 mg, 0.061 mmol) was treated with powdered KOH (6.8 mg, 
0.122 mmol). The product was isolated by column chromatography eluting with a hexane/
EtOAc mixture (2:1) as a colorless solid (Rf = 0.14, mp 74−76 °C). [α]D20 +50.3 (c = 0.90, 
CHCl3). Yield 19.2 mg (0.059 mmol, 96%). 1H NMR (500 MHz, CDCl3): δ 7.43−7.35 (m, 
3H), 7.28−7.24 (m, 2H), 7.12− 7.02 (m, 4H), 4.67 (dq, J = 10.8, 7.0 Hz, 1H), 4.38 (d, J = 
10.8 Hz, 1H), 3.64 (dd, J = 6.4, 3.5 Hz, 1H), 3.07 (s, 3H), 1.69 (dd, J = 6.9, 3.5 Hz, 1H), 
1.38 (t, J = 6.7 Hz, 1H), 1.13 (d, J = 7.0 Hz, 3H). 13C{1H} NMR (126 MHz, CDCl3): δ 
171.4, 161.8 (d, J = 245.6 Hz), 136.4, 133.9 (d, J = 3.1 Hz), 129.2 (+, 2C), 129.1 (+), 128.4 
(+, 2C), 126.2 (d, J = 7.8 Hz, +, 2C), 116.1 (d, J = 21.6 Hz, +, 2C), 80.0 (+), 55.4 (+), 51.5 
(+), 34.6, 27.6 (+), 23.3 (−), 15.1 (+). FTIR (NaCl, cm−1): 1647, 1510, 1233, 1152. HRMS 
(TOF ES): found 348.1382, calculated for C20H20FNO2Na (M + Na) 348.1376 (1.7 ppm).
(−)-(1S,3S,4S,7S)-7-(2,4-Dichlorophenyl)-4,5-dimethyl-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (25c).—This compound was synthesized according to the 
typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 
mg, 0.87 mmol, 1.0 equiv) and (1S,2S)-(+)-pseudoephedrine hydro-chloride (32) (264 mg, 
1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude 1-(2,4-
dichlorophenyl)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-
carboxamide (24c) was used at the cyclization step as is without additional purification. To 
this end, amide 24c (20 mg, 0.053 mmol) was treated with powdered KOH (5.9 mg, 0.106 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless solid (Rf = 0.54, mp 144−146 °C). Yield 16.4 mg (0.043 mmol, 
82%). [α]D20 −85.2 (c = 0.70, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.54 (d, J = 8.5 Hz, 
1H), 7.48−7.40 (m, 5H), 7.39 (d, J = 2.3 Hz, 1H), 7.28−7.24 (m, 1H), 5.16 (dq, J = 10.8, 7.0 
Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 4.22 (dd, J = 6.3, 3.2 Hz, 1H), 2.99 (s, 3H), 1.69 (dd, J = 
6.7, 3.2 Hz, 1H), 1.54 (t, J = 6.5 Hz, 1H), 1.18 (d, J = 7.0 Hz, 3H). 13C{1H} NMR (126 
MHz, CDCl3): δ 170.8, 136.9, 134.1, 133.8, 133.7, 132.2 (+), 131.2 (+), 129.2 (+, 2C), 
129.1 (+), 128.5 (+, 2C), 127.6 (+), 80.1 (+), 53.6 (+), 51.3 (+), 34.6, 27.9 (+), 22.3 (−), 15.1 
(+). FTIR (NaCl, cm−1): 1653, 1471, 1251, 1155. HRMS (TOF ES): found 376.0854, 
calculated for C20H20Cl2NO2 (M + H) 376.0871 (4.5 ppm).
(+)-(1R,3R,4R,7R)-7-(2,4-Dichlorophenyl)-4,5-dimethyl-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (ent-25c).—This compound was synthesized according 
to the typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid 
(14c) (200 mg, 0.87 mmol, 1.0 equiv) and (1R,2R)-(−)-pseudoephedrine hydrochloride 
(ent-32) (264 mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug 
crude 1-(2,4-dichlorophenyl)-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-
methylcycloprop-2-ene-1-carboxamide (ent-24c) was used at the cyclization step as is 
Maslivetc et al. Page 23













without additional purification. To this end, amide ent-24c (20 mg, 0.053 mmol) was treated 
with powdered KOH (5.9 mg, 0.106 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf = 0.54, 
mp 140−141 °C). Yield 16.8 mg (0.045 mmol, 84%). [α]D20 +81.8 (c = 0.70, CHCl3). 1H 
NMR (500 MHz, CDCl3): δ 7.55 (d, J = 8.5 Hz, 1H), 7.47−7.40 (m, 5H), 7.39 (d, J = 2.3 
Hz, 1H), 7.30−7.24 (m, 1H), 5.16 (dq, J = 10.9, 7.0 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 4.22 
(dd, J = 6.3, 3.1 Hz, 1H), 2.99 (s, 3H), 1.69 (dd, J = 6.7, 3.2 Hz, 1H), 1.54 (t, J = 6.5 Hz, 
1H), 1.18 (d, J = 7.0 Hz, 3H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.8, 136.9, 134.1, 
133.8, 133.7, 132.2 (+), 131.2 (+), 129.2 (+, 2C), 129.1 (+), 128.5 (+, 2C), 127.6 (+), 80.0 
(+), 53.6 (+), 51.3 (+), 34.6, 27.9 (+), 22.3 (−), 15.1 (+). FTIR (NaCl, cm−1): 1653, 1474, 
1253, 1152. HRMS (TOF ES): found 398.0702, calculated for C20H19Cl2NO2Na (M + Na) 
398.0691 (2.8 ppm).
(−)-(1S,3S,4S,7S)-4,5-Dimethyl-7-(naphthalen-1-yl)-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (25d).—This compound was synthesized according to the 
typical procedure from 1-(naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (14d) (200 
mg, 0.95 mmol, 1.0 equiv) and (1S,2S)-(+)-pseudoephedrine hydrochloride (32) (288 mg, 
1.43 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude N-((1S,
2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-(naphthalen-1-yl)cycloprop-2-ene-1-
carboxamide (24d) was used at the cyclization step as is without additional purification. To 
this end, amide 24d (20 mg, 0.056 mmol) was treated with powdered KOH (6.3 mg, 0.112 
mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc 
mixture (2:1) as a colorless solid (Rf = 0.30, mp 217−220 °C). Yield 16.2 mg (0.045 mmol, 
81%). [α]D20 −115.1 (c = 0.70, CHCl3). 1H NMR (500 MHz, CDCl3): δ 9.30 (dd, J = 8.6, 
1.0 Hz, 1H), 7.86−7.80 (m, 2H), 7.72 (dd, J = 7.1, 1.1 Hz, 1H), 7.67−7.61 (m, 3H), 
7.57−7.44 (m, 5H), 5.55 (dq, J = 10.8, 7.0 Hz, 1H), 4.48 (d, J = 10.8 Hz, 1H), 3.96 (dd, J = 
6.3, 2.8 Hz, 1H), 2.95 (s, 3H), 1.84 (dd, J = 6.3, 2.8 Hz, 1H), 1.23 (d, J = 7.0 Hz, 3H), 1.20 
(t, J = 6.3 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.8, 137.3, 134.7, 134.6, 133.6, 
129.4 (+, 2C), 129.1 (+), 128.9 (+), 128.5 (+, 2C), 128.2 (+), 127.6 (+), 126.5 (+), 126.5 (+), 
125.4 (+), 124.9 (+), 80.0 (+), 52.4 (+), 51.0 (+), 34.1, 27.9 (+), 21.6 (−), 15.3 (+). FTIR 
(NaCl, cm−1): 1645, 1391, 1152. HRMS (TOF ES): found 380.1638, calculated for 
C24H23NO2Na (M + Na) 380.1626 (3.2 ppm).
(+)-(1R,3R,4R,7R)-4,5-Dimethyl-7-(naphthalen-1-yl)-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (ent-25d).—This compound was synthesized according 
to the typical procedure from 1-(naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (14d) 
(200 mg, 0.95 mmol, 1.0 equiv) and (1R,2R)-(−)-pseudoephedrine hydrochloride (ent-32) 
(288 mg, 1.43 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude 
N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-(naphthalen-1-yl)cycloprop-2-
ene-1-carboxamide (ent-24d) was used at the cyclization step as is without additional 
purification. To this end, amide ent-24d (20 mg, 0.056 mmol) was treated with powdered 
KOH (6.3 mg, 0.112 mmol). The product was isolated by column chromatography eluting 
with a hexane/EtOAc mixture (2:1) as a colorless solid (Rf = 0.30, mp 222−224 °C). Yield 
16.8 mg (0.047 mmol, 84%). [α]D20 +118.5 (c = 0.70, CHCl3). 1H NMR (500 MHz, 
CDCl3): δ 9.30 (dd, J = 8.6, 1.1 Hz, 1H), 7.87−7.78 (m, 2H), 7.72 (dd, J = 7.2, 1.2 Hz, 1H), 
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7.69−7.60 (m, 3H), 7.58− 7.44 (m, 5H), 5.55 (dq, J = 10.9, 7.0 Hz, 1H), 4.48 (d, J = 10.8 Hz, 
1H), 3.96 (dd, J = 6.3, 2.8 Hz, 1H), 2.95 (s, 3H), 1.84 (dd, J = 6.2, 2.8 Hz, 1H), 1.23 (d, J = 
7.0 Hz, 3H), 1.20 (t, J = 6.3 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.8, 137.3, 
134.7, 134.6, 133.6, 129.4 (+, 2C), 129.1 (+), 128.9 (+), 128.5 (+, 2C), 128.2 (+), 127.6 (+), 
126.5 (+), 126.5 (+), 125.4 (+), 124.9 (+), 80.0 (+), 52.4 (+), 51.0 (+), 34.1, 27.9 (+), 21.6 
(−), 15.3 (+). FTIR (NaCl, cm−1): 1645, 1392, 1151. HRMS (TOF ES): found 380.1608, 
calculated for C24H23NO2Na (M + Na) 380.1624 (4.7 ppm).
(+)-(1S,3R,4S,7S)-4,5-Dimethyl-3,7-diphenyl-2-oxa-5-azabicyclo-[5.1.0]octan-6-
one (28a).—This compound was synthesized according to the typical procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and (1R,
2S)-(−)-ephedrine hydrochloride (33) (378 mg, 1.88 mmol, 1.5 equiv). After extraction and 
filtration through a silica plug crude N-((1R,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-
methyl-1-phenylcycloprop-2-ene-1-carboxamide (27a) was used at the cyclization step as is 
without additional purification. To this end, amide 27a (20 mg, 0.065 mmol) was treated 
with powdered KOH (7.3 mg, 0.13 mmol). The product was isolated by column 
chromatography eluting with a hexane/EtOAc mixture (3:2) as a colorless glass (Rf = 0.28). 
[α]D20 +77.0 (c = 0.70, CHCl3). Yield 16.8 mg (0.055 mmol, 84%). 1H NMR (500 MHz, 
CDCl3): δ 7.36−7.29 (m, 5H), 7.27−7.19 (m, 3H), 7.08−7.03 (m, 2H), 4.64 (qd, J = 7.2, 4.2 
Hz, 1H), 4.51 (d, J = 4.3 Hz, 1H), 3.62 (dd, J = 6.2, 3.4 Hz, 1H), 2.70 (s, 3H), 1.89 (dd, J = 
7.0, 3.4 Hz, 1H), 1.62 (t, J = 6.6 Hz, 1H), 1.08 (d, J = 7.2 Hz, 3H). 13C{1H} NMR (126 
MHz, CDCl3): δ 171.3, 138.2, 136.5, 129.0 (+, 2C), 128.6 (+), 128.2 (+, 2C), 127.8 (+, 2C), 
126.8 (+), 124.6 (+, 2C), 81.2 (+), 59.4 (+), 52.3 (+), 35.1, 29.0 (+), 22.6 (−), 14.6 (+). FTIR 
(NaCl, cm−1): 1648, 1497, 1170. HRMS (TOF ES): found 330.1484, calculated for 
C20H21NO2Na (M + Na) 330.1470 (4.2 ppm).
(+)-(1S,3R,4S,7S)-7-(2,4-Dichlorophenyl)-4,5-dimethyl-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (28c).—This compound was synthesized according to the 
typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (150 
mg, 0.65 mmol, 1.0 equiv) and (1R,2S)-(−)-ephedrine (33) (198 mg, 0.98 mmol, 1.5 equiv). 
After extraction and filtration through a silica plug crude 1-(2,4-dichlorophenyl)-N-((1R,
2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-carboxamide (27c) was 
used at the cyclization step as is without additional purification. To this end, amide 27c (60 
mg, 0.16 mmol) was treated with powdered KOH (18 mg, 0.32 mmol). The product was 
isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) as a 
colorless solid (Rf = 0.26, mp 152−157 °C). Yield 52.2 mg (0.139 mmol, 87%). [α]D20 
+27.9 (c = 0.7, CHCl). 1 3 H NMR (500 MHz, CDCl3): δ 7.7 (d, J = 8.5 Hz, 1H), 7.4 (d, J = 
2.3 Hz, 1H), 7.3−7.3 (m, 3H), 7.3−7.2 (m, 3H), 5.4−5.3 (m, 1H), 4.7 (d, J = 4.4 Hz, 1H), 4.3 
(dd, J = 6.2, 3.1 Hz, 1H), 2.6 (s, 3H), 1.8 (dd, J = 6.6, 3.1 Hz, 1H), 1.5 (t, J = 6.4 Hz, 1H), 
1.1 (d, J = 7.1 Hz, 3H). 13C{1H} NMR (126 MHz, CDCl3): δ 170.8, 136.8, 133.9, 133.9, 
133.9 (+), 133.9, 130.7 (+), 128.6 (+), 128.3 (+, 2C), 127.7 (+, 2C), 127.7 (+), 81.1 (+), 56.6 
(+), 51.4 (+), 34.4, 29.5 (+), 22.9 (−), 14.3 (+). FTIR (NaCl, cm−1): 1647, 1474, 1167. 
HRMS (TOF ES): found 398.0676, calculated for C20H19Cl2NO2Na (M + Na) 398.0691 
(3.8 ppm).
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Structures and yields of racemic cyclization products 17. Yields of purified materials are 
provided.
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Structures and yields of enantiopure cyclization products 19. Yields of purified materials are 
provided.
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Structures and yields of chiral cyclization products 25 and 28. Yields of purified materials 
are provided.
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Table 1.
Biological Activities of 2-Oxa-5-azabicyclo[5.1.0]octan-6-ones
MIC, μM M. abscessus IC50, μM M. abscessus IC50, μM HeLa
19aa 100 ± 6.5 N/A >100
19ab 50 ± 10.6 6.25 ± 0.07 79.9 ± 8.5
19ba >100 >100 >100
19bb 50 ± 2.3 3.13 ± 0.04 85.1 ± 4.9
19ca 100 ± 3.8 25.4 ± 3.0 >100
19cb >100 N/A >100
25a >100 >100 >100
ent-25a >100 >100 >100
25d >100 >100 103.2 ± 19.4
28a >100 >100 >100
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